9 January 2008

The Company Announcements Office
ASX Limited

BY E-LODGEMENT

Dear Sir/Madam

DISPATCH OF NEUREN RIGHTS ISSUE OFFER DOCUMENTS

Neuren Pharmaceuticals Limited (ASX Code: NEU) hereby confirms that the offer
documents (attached) relating to the announced rights issue have been dispatched.

By Order of the Board

Yours sincerely

Mr Rob Turnbull
Chief Financial Officer
NEUREN PHARMACEUTICALS LIMITED
1181152 / ARBN 111 496 130

RIGHTS ISSUE
LETTER OF OFFER

Dated: 19 December 2007

For a 1 for 2 non-renounceable rights issue by Neuren Pharmaceuticals Limited to existing Australian and New Zealand resident Shareholders of 72,369,626 ordinary shares.

Record date: 2 January 2008

This is an important document and you should read it carefully. If you have any queries or concerns you should contact the Company or your own legal or financial advisor.
IMPORTANT INFORMATION

1. This Letter of Offer is dated 19 December 2007.

2. The Offer of New Shares in this Letter of Offer is only available for acceptance by Eligible Shareholders. This Letter of Offer does not constitute an offer in any place in which or to any person to whom, it would be unlawful to make such an offer.

3. No person is authorised to give any information or to make any representation in connection with the Offer that is not contained in this Letter of Offer. Any information or representation that is not contained in this Letter of Offer may not be relied on as having been authorised by Neuren in connection with the Offer.

4. This is a Letter of Offer for an Offer of continuously quoted securities (as defined in the Corporations Act) of Neuren and has been prepared in accordance with section 708AA of the Corporations Act. In broad terms, section 708AA relates to rights issues by certain companies that do not require the provision of a prospectus or other disclosure document. Accordingly, the level of disclosure in this Letter of Offer is significantly less than that required in a prospectus. Eligible Shareholders should therefore rely upon their own knowledge of Neuren, refer to disclosures already made by it to ASX, and refer to their professional adviser before deciding whether to accept the Offer.

5. Eligible Shareholders will receive an Application Form with this Letter of Offer.

6. The information contained in this Letter of Offer is important and should be read in full.

IMPORTANT DATES

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Announcement of Rights Issue</td>
<td>19 December 2007</td>
</tr>
<tr>
<td>Lodgement Date – Letter of Offer (LOO), ASX Appendix 3B and cleansing notice lodged with ASX</td>
<td>19 December 2007</td>
</tr>
<tr>
<td>Ex Date – The date on which the Shares commence trading without the Entitlement to participate in the Offer</td>
<td>24 December 2007</td>
</tr>
<tr>
<td>Record Date for calculation of Entitlements (7.00 pm AEST)</td>
<td>2 January 2008</td>
</tr>
<tr>
<td>LOO, including Application Form, sent to Shareholders and lodgement of second cleansing notice – Offer opens</td>
<td>8 January 2008</td>
</tr>
<tr>
<td>Closing Date for receipt of acceptances, at 5 p.m. AEST</td>
<td>25 January 2008</td>
</tr>
<tr>
<td>Shortfall Notification Date</td>
<td>31 January 2008</td>
</tr>
<tr>
<td>Allotment of New Shares</td>
<td>1 February 2008</td>
</tr>
<tr>
<td>Expected despatch of statement of holdings for New Shares</td>
<td>Not later than 5 February 2008</td>
</tr>
</tbody>
</table>

These dates are subject to change and are indicative only. Neuren reserves the right to amend this timetable, with the consent of the Underwriter where required, including, subject to the Corporations Act and the Listing Rules, to extend the Closing Date.

DEFINED TERMS

Words defined in the glossary “Definitions and Interpretations” at the end of this Letter of Offer are used in this Letter of Offer with an initial capital letter.
Dear Shareholder,

Neuren Pharmaceuticals Limited ("Neuren" or the "Company") is making this pro-rata rights issue offer of up to 72,369,626 new ordinary shares to its New Zealand and Australian resident Shareholders, at A$0.14 per New Share for Australian resident Shareholders and NZ$0.16 per New Share for New Zealand resident Shareholders. This Offer is partially underwritten to A$7.1 million by Taylor Collison Limited.

Approximately 37,600,000 of the New Shares are being offered to Australian resident Shareholders. Neuren is taking advantage of exemptions under Australian securities laws which mean that a prospectus or disclosure document is not required in Australia for the purpose of making the Offer to Australian resident Shareholders. The exact number of New Shares being offered to Australian resident Shareholders will be determined on the Record Date based on the offer ratio of one New Share for every two existing Shares held by Australian resident Shareholders. The terms of the Offer are the same for all Shareholders in Australia and New Zealand, including being able to apply for additional shares under the Shortfall described on page 6.

Your Entitlement to New Shares is set out in the enclosed Application Form, and instructions on how to apply for your Entitlement, and should you wish, additional New Shares in excess of your Entitlement from the Shortfall, are set out in the Letter of Offer on pages 7 to 9.

Neuren is making good progress with all of its product candidates. We have a robust product portfolio focused on psychiatric and cognitive effects of neurological injury and disease. Three of our drugs are in clinical trials for four central nervous system indications, with efficacy results expected in 2009. Following these, Neuren potentially only has to conduct 1 to 2 more pivotal trials to make a new drug application to be able to market each drug. We also have a strong preclinical pipeline in neurology, cancer and metabolic diseases presenting significant partnership and/or licensing opportunities for which we are currently in discussion.

Further details on the status of our pipeline are set out in the "Prospects" section on pages 14 to 16.

The capital raised in a fully subscribed Offer of A$10.1 million (gross) will support completion of the first Glypromate® Phase 3 trial as well as associated overhead and corporate operating expenses. The underwritten amount of A$7.1 million which is the minimum that will be raised under this Offer will trigger conversion of the outstanding convertible notes held by the former Hamilton Pharmaceuticals shareholders, will support Glypromate® clinical trial costs and overhead through 2008 and will allow other capital raising, joint venture and licensing opportunities currently underway to be pursued.

The Board recommends this Offer to you and thanks those Shareholders who continue to support the Company.

Yours sincerely

[Signature]

Chairman
SUMMARY OF OFFER

The information set out in this section is not intended to be comprehensive and should be read in conjunction with the full text of this Letter of Offer.

Introduction

Neuren Pharmaceuticals Limited ("Neuren" or the "Company") is offering 72,369,626 ordinary shares to the registered Australian and New Zealand resident holders of ordinary shares in the Company as at 2 January 2008 in the ratio of one new ordinary share for every two ordinary shares held at that date, at a price of A$0.14 per New Share to Australian resident Shareholders and NZ$0.16 per New Share to New Zealand resident Shareholders, payable on application (this "Offer"). Assuming this Offer is fully subscribed, the New Shares will represent 33.3% of Neuren’s ordinary shares as at the date of this Letter of Offer. Your Entitlement to be issued New Shares under this Offer is non-renounceable – i.e., it may not be sold or otherwise transferred.

This Letter of Offer has been prepared in compliance with Australian securities laws for the purpose of making the Offer to Australian resident Shareholders only.

The New Shares will rank equally in all respects with the Company’s Existing Shares. The Offer may be accepted in full or in part and there is no minimum level of Entitlement that must be accepted by a Shareholder in order to participate in the Offer. Shareholders can apply, in the “Shortfall Application” section of the Application Form, for New Shares in excess of their Entitlement that have not been taken up by other Shareholders.

The Offer is partially underwritten by Taylor Collison Limited (ACN 008 172 450) for up to 50,700,000 New Shares. A Shareholder in which Mr Trevor Scott, a director of the Company, has an interest has agreed to sub-underwrite the Offer for up to 6,570,000 New Shares.

An application will constitute an irrevocable offer by the applicant to acquire the number of New Shares specified in the application. If the full amount of the subscription monies payable for the New Shares subscribed for (the “Application Monies”) is not paid on application or a cheque does not clear, an application may be rejected or an allocation cancelled.

As this Offer is partially underwritten, the Directors have not established a minimum amount which must be raised before the Directors will accept subscriptions and allot New Shares under this Offer.

Instructions on how to apply for the New Shares are set out under the headings “How much do I pay?” on pages 7 to 9 and on the Application Form itself.

No Overseas Offers

This Letter of Offer does not constitute an offer in any jurisdiction in which, or to any person to whom, it would be unlawful to make such an offer. Where this Letter of Offer has been despatched to investors domiciled outside Australia and where that country’s securities code and legislation requires registration, this Letter of Offer is provided for information purposes only. Non-resident investors should consult their professional advisers as to whether any governmental or other consents are required or whether formalities need to be observed to enable them to participate in the Shortfall.

The Company is of the view that it is unreasonable to make the Offer to shareholders outside of Australia and New Zealand having regard to:

- the number of Shareholders outside of Australia and New Zealand;
- the number and value of the securities that could be offered to Shareholders outside of Australia and New Zealand; and
Neuren Pharmaceuticals Limited
Letter of Offer

- the cost of complying with the legal requirements and requirements of regulatory authorities in the overseas jurisdictions.

Accordingly, the Company is not required to make the Offer to Shareholders outside of Australia and New Zealand (though this Letter of Offer will be sent to Shareholders outside these jurisdictions for information purposes only).

Stock Exchange Listing
Application has been made to ASX for permission to list the securities and all the requirements of ASX relating thereto that can be complied with on or before the date of this Letter of Offer have been duly complied with. However, ASX accepts no responsibility for any statement in this Letter of Offer. If the ASX does not grant permission for quotation of the New Shares offered pursuant to this Letter of Offer within three (3) months after the date of this Letter of Offer, or such longer period as is permitted, none of the New Shares offered by this Letter of Offer will be allotted or issued. In these circumstances, the Company will repay all application monies, without interest.

DETAILS OF THE OFFER

What sort of investment is this?
Offer
This is an offer by Neuren of a maximum of 72,369,626 ordinary shares to the Australian and New Zealand resident registered holders of ordinary shares in the Company as at 7.00 p.m. AEST on 2 January 2008 in the ratio of one new ordinary share for every two ordinary shares held at that date, at a price of A$0.14 per New Share to Australian resident Shareholders and NZ$0.16 per New Share to New Zealand resident Shareholders, payable on application. Assuming this Offer is fully subscribed, the New Shares will represent 33.3% of Neuren’s ordinary shares as at the date of this Letter of Offer. Your Entitlement to be issued New Shares under this Offer is non-renounceable – i.e, it may not be sold or otherwise transferred.

To the extent that there is a Shortfall, you may apply for additional New Shares (over and above your Entitlement) by a Shortfall Application. Acceptance of Shortfall Applications will be considered by the Company in its sole discretion.

Except for applications in respect of the Shortfall, registered holders of ordinary shares may not apply for New Shares in excess of the Entitlement. Application Monies for New Shares in excess of Entitlements will be refunded without interest. Refunds will be posted within seven calendar days of allotment of the New Shares.

New Shares
Each New Share issued shall rank equally in all respects with the Existing Shares in the Company at the time of issue and will provide you with the right to:

- an equal share with other ordinary shares in the Company in dividends, if any, authorised by the Board;
- attend and vote at meetings of the Company, including the right to cast one vote on a poll held at such meetings;
- receive certain Company information;
- an equal share with other ordinary shares in the Company in the distribution of any surplus assets on liquidation of the Company; and
- other rights conferred on shareholders by the Constitution and the Companies Act.

The Constitution may be viewed during normal business hours at the Registered Office of the Company (the address of which is set out on page 7 or online at the website of the Company (www.neurenpharma.com) or the ASX (www.asx.au.com).

See the section entitled “Description of Shares” on pages 18 to 20 for further information relating to the New Shares.
Application has been made to ASX for permission to list the securities and all the requirements of ASX relating thereto that can be complied with on or before the date of this Letter of Offer have been duly complied with. However, ASX accepts no responsibility for any statement in this Letter of Offer. If the ASX does not grant permission for quotation of the New Shares offered pursuant to this Letter of Offer within three (3) months after the date of this Letter of Offer, or such longer period as is permitted, none of the New Shares offered by this Letter of Offer will be allotted or issued. In these circumstances, the Company will repay all application monies, without interest.

Shortfall

The Directors reserve the right, by no later than 25 April 2008, to place any New Shares which are not taken up by holders of Existing Shares under this Offer, or which because of fractional Entitlements are not otherwise offered, to such persons and in such manner as the Directors consider equitable and in the interests of the Company, provided that the New Shares offered under the Shortfall are issued at not less than the price under the Offer and the terms and conditions of the issue of such New Shares are not materially more favourable to the persons to whom they are issued than the terms of this Offer.

An application to participate in any Shortfall may be made pursuant to this Letter of Offer by a Shareholder in Australia, although other persons may apply for the Shortfall to the extent permitted by relevant securities laws, provided that the Directors may not participate in any Shortfall.

The Directors will allocate any Shortfall in such manner as the Directors consider equitable and in the interests of the Company. The Directors do not guarantee that any Shortfall Application will be successful. In the event a Shortfall Application is not accepted (whether in whole or in part) monies in relation to the New Shares applied for and not allocated will be refunded in full without interest within 7 days of notification of the Shortfall by the Company to ASX.

The Company may at its discretion pay a commission on a Shortfall Application received, in particular in respect of applications bearing a broker stamp of a member organisation of the ASX, provided the Shortfall Application is accepted by the Directors and New Shares are subsequently allotted. The payment of any commission will be made 14 days after acceptance by the Company of a Shortfall Application.

It should also be noted that the Company has entered into an agreement in respect of the underwriting of part of the Shortfall, as described in more detail under the heading “Underwriting” below.

Underwriting

The Offer is partially underwritten by Taylor Collison Limited (ACN 008 172 450) (the “Underwriter”) pursuant to an agreement between the Underwriter and the Company dated 19 December 2007. The terms of the underwrite are such that the Company may call upon the Underwriter to subscribe for, or cause the subscription for, 50,700,000 New Shares less the number of New Shares subscribed for under this Offer (including subscriptions for the Shortfall). By way of example, if subscriptions were received and accepted for 10,000,000 New Shares, the Company could call upon the Underwriter to subscribe, or cause the subscription, for 40,700,000 New Shares. If subscriptions were received in respect of 50,700,000 or more New Shares, the Company could not call upon the Underwriter to subscribe for New Shares.

A Shareholder in which Mr Trevor Scott, a director of the Company, has an interest has agreed to sub-underwrite the Offer for up to 6,570,000 New Shares.

Details of the underwriting fee payable to the Underwriter are set out on page 9, under the heading “What are the charges?”. 
Who is involved in providing it for me?

Names and addresses

Issuer
The issuer of the New Shares that are subject to this Letter of Offer is Neuren Pharmaceuticals Limited (NZ registered company number 1181152; ARBN 111 496 130).

New Zealand Registered Office
Neuren Pharmaceuticals Limited
Level1, 103 Carlton Gore Road
Newmarket, Auckland

Activities
Neuren, which was incorporated on 17 December 2001, is developing drugs for neurological disorders, metabolism and cancer. The drugs target acute indications of brain injury such as cognitive impairment resulting from cardiac surgery and traumatic brain injury, psychiatric symptoms of stroke, as well as chronic conditions such as Parkinson’s and Alzheimer’s diseases.

Neuren has four lead candidates; Glypromate®, Motiva™ and NNZ-2566 presently in clinical development to treat four different neurological conditions, and NNZ-2591 in preclinical development for Parkinson’s disease dementia and other chronic neurodegenerative conditions.

Neuren has operations in New Zealand (Auckland based head office), Australia and the United States, and is listed on the Australian Securities Exchange (ASX: NEU).

The principal activities of the Company are described in more detail in the section of this Letter of Offer entitled “Prospects” on pages 14 to 16.

No person or entity guarantees the securities offered in this Letter of Offer.

How much do I pay?

Share Price
You must apply for a specific number of New Shares and you must pay the full subscription price on application. The subscription price is A$0.14 per New Share.

Acceptance of the Offer
The number of New Shares to which you are entitled is set out in the Application Form accompanying this Letter of Offer. The number of New Shares to which shareholders are entitled will, in the case of fractional Entitlements, be rounded down to the nearest whole number. Your rights to subscribe for New Shares are non-renounceable.

This Offer may be accepted in full or in part. There is no minimum acceptance level. Shareholders can apply, on the Application Form, for an allocation of New Shares in excess of their Entitlement from the Shortfall.

Applications for New Shares must be made so as to be received no later than 5 p.m. (AEST) on Friday 25 January 2008 (“Closing Date”). The Directors reserve the right to extend the Closing Date.

To subscribe for a certain number of New Shares, you must send the total subscription payable for those New Shares (the “Application Monies”), together with a completed Application Form (accompanying this Letter of Offer), to Neuren’s share registrar, Link Market Services Limited.
Any Application Monies paid by you for New Shares will be held on trust for you until the Company effects the issue to you of the relevant number of New Shares, at which time the relevant funds will be released beneficially to the Company.

Listed below are the steps to be taken if you wish to:

- accept your Entitlement in full or in part; or
- apply for additional New Shares to be allocated from the Shortfall.

**To accept all or part of your Entitlement**

Complete and sign the Entitlement & Acceptance section of the Application Form specifying the number of New Shares comprising your Entitlement you wish to accept) and send the Application Form and a cheque made payable to: “Neuren Pharmaceuticals Limited Trust Account” and crossed “Not Negotiable”. All cheques must be in Australian dollars and sent with the completed Application Form to:

**Mail to:**
The Neuren Share Offer
Link Market services Limited
Locked Bag A14
Sydney South NSW 1235

**or Deliver in person to:**
Link Market services Limited
Level 12, 680 George Street
Sydney NSW 2000

(Do not use this address for mailing purposes)

**To apply for additional New Shares**

If applicants wish to participate in any Shortfall that may arise under this Offer, they should complete the Shortfall Application section of the Application Form attached to this Letter of Offer. The completed Application Form together with a cheque made payable to “Neuren Pharmaceuticals Limited Trust Account” and crossed “Not Negotiable” should be sent before the Closing Date to:

**Mail to:**
The Neuren Share Offer
Link Market services Limited
Locked Bag A14
Sydney South NSW 1235

**or Deliver in person to:**
Link Market services Limited
Level 12, 680 George Street
Sydney NSW 2000

(Do not use this address for mailing purposes)

The Directors will allocate any Shortfall in such manner as the Directors consider equitable and in the interests of the Company. The Directors do not guarantee that any Shortfall Application will be successful. In the event the Shortfall Application is not accepted (whether in whole or in part) monies in relation to the New Shares applied for and not allocated will be refunded in full without interest within 7 days of notification of the Shortfall by the Company to ASX.

The completed Application Form must be received not later than 5.00 p.m. (AEST) on 25 January 2008 (or such later closing date as determined by the Company).

Please note that if you do not accept all or part of your Entitlement in accordance with the instructions set out above, any Entitlement not accepted will form part of the Shortfall.

Please also note that post-dated cheques will not be accepted. If the full amount of the Application Monies is not paid upon application or a cheque does not clear, your application may be rejected or any allocation of New Shares made to you may be cancelled.

An application will constitute an irrevocable offer by you to acquire the number of New Shares specified, on the terms and conditions set out in this Letter of Offer and the Application Form. By submitting an application you agree to be bound by these terms and conditions and the Constitution. Applications cannot be revoked or withdrawn and Application Monies (except in the case of Entitlement over-subscription or applications to participate in the Shortfall that are not accepted by the Company) will not, therefore, be refunded. As indicated above, you should note that the Company reserves the right to extend the Offer.
Neuren Pharmaceuticals Limited
Letter of Offer

and that such extension may result in the dates referred to in the table on page 1 of this Letter of Offer being altered. Any such changes will be advised through the ASX companies announcements platform.

What are the charges?
There are no charges payable by subscribers for the New Shares in addition to the subscription price. All expenses in respect of this Offer are being met by the Company.

As detailed on page 6, the Offer is partially underwritten by the Underwriter pursuant to an underwriting agreement between it and the Company dated 19 December 2007. A 4.0% underwriting fee and a 2.0% management fee totalling A$425,880 plus GST (if applicable) will be payable by the Company on the underwritten amount to the Underwriter. The Company estimates that its costs in respect of the Offer will be A$26,500 plus GST, excluding the underwriting and management fee. In addition the Underwriter will be granted 3,000,000 A$0.25 options over ordinary shares, with a three year term, on completion of the Offer.

A Shareholder in which Mr Trevor Scott, a director of the Company, has an interest has agreed to sub-underwrite the Offer for up to 6,570,000 New Shares, for which it will receive a sub-underwriting commission of 2.5% of the amount ultimately sub-underwritten. This sub-underwriting fee is to be paid by the Underwriter from its fees noted above.

What returns will I get?

Dividends
New Shares issued as a result of this Offer will rank equally in all respects, including as to dividends and voting entitlements, with the Existing Shares on issue at the time of allotment. Shareholders will be entitled to receive or benefit from any dividends paid by the Company in respect of New Shares and to any other returns attaching to the New Shares. However, the Company is not intending to pay dividends in the foreseeable future, given that it is intended that the Company will use all available funds for its clinical development and research programmes.

Sale of New Shares
Shareholders may benefit from any increase in the market price of their New Shares if they sell them, however the market price of the New Shares may also decline. Factors which may have an influence on the share price of Neuren ordinary shares and, consequently, on returns from the sale of New Shares include:

- prevailing share market conditions;
- general economic conditions;
- interest rate rises or reductions;
- significant changes in the operations or results of Neuren;
- a sale of a significant parcel of Neuren ordinary shares;
- a take-over offer by a third party; and
- the risks described in this Letter of Offer under the heading “What are my risks?” below.

Taxation
Your return from the New Shares may be affected by taxes or changes to taxation laws. In certain circumstances, gains on the sale of New Shares may be taxable, however you should contact your own financial or legal adviser to seek advice concerning the tax consequences of owning or selling New Shares in view of your own particular circumstances.

No guarantee or promise
Neither Neuren, its Directors, nor any person associated with this Offer, guarantees the New Shares or that a dividend will be paid on the New Shares or that the issue price of A$0.14 per New Share will be recouped. No amount of returns (whether by way of dividend or return on sale or otherwise) on the New Shares is promised or guaranteed by any person. Accordingly, the dates on which, or the frequency with which, returns (if any) on the New Shares will be due and paid are unknown.
What are my risks?

**General risk factors**

Investments in biopharmaceutical companies can be considered speculative. Risks associated with investment in the Company include risks of a general nature relating to investment in shares and securities generally where the company invested in has a small market capitalisation together with risks particular to investment in the Company, which risks relate to the nature of its activities, being biotechnology research and development.

Investors in the Company will also be subject to normal risks relating to the general levels of economic activity and macro-economic factors beyond the control of the Company including share market conditions which may affect the share market and share prices generally. General risk factors which may have an influence on the share price are described above under the heading “What returns will I get?” and the occurrence of such events, or the specific risk factors detailed below, could result in investors in the Company being unable to recover, or receive any returns on their investment.

**Specific risk factors**

There are a number of specific risks that may affect Neuren’s operating performance and, consequently, the value of its Shares and returns on the New Shares. Key risks which may affect the value of the New Shares and returns on the New Shares are as follows:

- **Reliance on Key Personnel** – Neuren currently employs a number of key management and scientific personnel, and in part its future depends on retaining and attracting suitably qualified personnel. Failure to do so could materially adversely affect its business, operating results and financial prospects.

- **Contract Risks Generally** – Neuren operates through a series of contractual relationships with licensors, sublicensees, independent contractors, distributors and suppliers. All contracts carry risks associated with the performance by the parties thereto of their obligations as to time and quality of work performed.

- **Risk as to Technical Capacity** – Neuren intends to carry out development work using appropriately chosen scientific research organisations. As such, it will be subject to the risk that staff in those organisations may have lesser technical capacity than needed to achieve the results sought to be obtained from any development program and the results sought to be obtained may not be obtained or results apparently obtained may be inaccurate as a result of flawed research or development.

- **Intellectual Property and Proprietary Rights** – Neuren regards the content of certain of its technology as proprietary and relies primarily on a combination of copyright, patent and trade secrecy laws and employee and third party non-disclosure agreements to protect its rights. However, no assurances can be given that employees and/or third parties will not breach non-disclosure agreements or infringe or misappropriate Neuren’s rights. Further, no assurance can be given that others will not challenge the ownership or validity of those proprietary rights by attacking either Neuren or patent holders from whom it has acquired licenses. Litigation may be necessary from time to time to enforce and protect Neuren’s rights. Such litigation can be costly and could have adverse effects on its activities, business, operating results and financial position. It is possible that other parties may assert intellectual property infringement, unfair competition or like claims against Neuren under copyright, trade secret, patent or other laws. While Neuren is not aware of any claims of this nature in relation to any of the intellectual property rights in which it has interests, such claims, if made, may harm, directly and indirectly, its business. If Neuren is forced to defend against claims of intellectual property infringement, whether they are with or without merit or are determined in its favour, it might face costly litigation and diversion of management’s attention. As a result of such disputes, Neuren may have to develop non-infringing technology or enter into royalty or licensing agreements. Such agreements, if necessary, may be unavailable on terms acceptable to Neuren, or at all. If there is a successful claim of intellectual property infringement or unfair competition against Neuren and it is unable to develop non-infringing technology or license the infringed or similar technology or content on a timely basis, it could harm Neuren’s business, operations and financial condition.

- **Technological Development** – Neuren’s future success will depend in no small part on its ability to develop products that are able to compete in a global marketplace. No assurance can be given that the research and development activities will lead to the development of such products.

- **Competition** – Neuren’s current and potential future competitors might include companies with significantly greater resources than those possessed by the Company. These competitors may develop products or services that are
more effective and/or cheaper than those being developed by Neuren, and as a consequence its products or services may become uncompetitive, resulting in adverse effects on revenue, margins and profitability.

- **Product Development** – There are many risks inherent in the development of biotechnology products. They can be subject to many failures during manufacturing and clinical trials or may fail to achieve sufficient robustness and reliability. Neuren cannot guarantee that the development work being undertaken or the milestones sought will result in the development of any products, or even if they do, that those products will be commercially successful.

- **Sufficiency of Funding** – Neuren has a business plan which will require a high level of expenditure until product revenue streams are established and therefore it expects to continue to incur additional net losses until then. In the future, Neuren will need to raise further financing through other public or private equity financings, collaborations or other arrangements with corporate sources, or other sources of financing to fund operations and achieve milestones. There can be no assurance that such additional financing, if available, can be obtained on terms reasonable to Neuren. In the event Neuren is unable to raise additional capital, future operations will need to be curtailed or discontinued.

- **Regulatory Risks** – Neuren’s operations will require approvals from regulatory authorities which may not be forthcoming or which may not be able to be obtained on acceptable terms. While Neuren has no reason to believe that all requisite approvals will not be forthcoming, investors should be aware that Neuren cannot guarantee that any requisite approvals will be obtained. A failure to obtain any approvals would mean that Neuren’s ability to develop or operate any project may be limited or restricted either in part or absolutely.

- **Risk as to Profitability** – Neuren’s ability to pay dividends will depend on it generating revenue and then deriving sufficient after-tax profits to be able to do so. Neuren is not presently profitable and it may not at any time be so.

- **No Valuation** – No formal or informal valuation has been completed of our intellectual property or assets. We make no representation as to the value of our intellectual property or assets.

- **Risks Related to Liquidity** – Neuren’s Existing Shares quoted on the ASX have limited liquidity. Accordingly, if Neuren successfully applies for quotation on the ASX of the New Shares, there can be no assurance that investors will have sufficient liquidity to sell their Shares through the ASX on a timely basis, at an acceptable price, or at all. As a result of the foregoing, investors may be forced to sell any New Shares acquired in connection with this offering for less than anticipated or even at a loss, or hold their New Shares for longer than anticipated.

- **Generally** – The possibility exists that, for a wide range of reasons, Neuren’s present strategies, plans, policies, intentions and expectations may not be able to be implemented.

### Your liability and consequences of insolvency

The New Shares allotted under this Offer will be issued fully paid and you will have no liability to Neuren for any further payment in respect of the New Shares.

If the Company becomes insolvent, you would have no obligation to pay any more money to the Company or any other person. Claims on assets of the Company, in the event of the Company being put into liquidation, that rank ahead of the claims of shareholders in the Company are:

- all creditors of the Company, both secured and unsecured; and
- those claims given priority by legislation such as claims for liquidation costs, employees’ wages and taxes.

After all such claims have been paid and made, any remaining assets will be available for distributions to the Company’s Shareholders who will rank equally among themselves. It is reasonably foreseeable that, on termination of your Shares as a consequence of the Company being put into liquidation, you will have received, in total, less than the amount you have paid for the Shares.

### Can the investment be altered?

The full terms of this Offer are set out in this Letter of Offer. Those terms may be altered by the Company by an amendment to this Letter of Offer, details of which would be communicated to you and the ASX. However, those terms cannot be altered without your consent once your application for New Shares has been accepted.
The rights attaching to the New Shares are set out under the heading “What sort of investment is this?” and in the section headed “Description of Shares” on pages 18 to 20 of this Letter of Offer.

The rights conferred on the Company’s Shareholders are set out in the Companies Act and the Constitution, and also the applicable Listing Rules of the ASX. Shareholders’ rights may be negated, altered or added to by an amendment of the Constitution, which may be made by a special resolution of Shareholders. A special resolution requires the approval of 75% of the votes of shareholders affected by the relevant matter, to be valid.

Neuren may not take any action which would affect the rights of Shareholders without approval by special resolution of those Shareholders whose rights would be affected by the action in question.

Certain major transactions and those that would change the nature of the Company’s business also require the approval of a special resolution.

**How do I cash in my investment?**

Except as otherwise prescribed by law, you have no right to receive back from the Company the amount subscribed for the New Shares offered under this Letter of Offer, except in circumstances where the Company is being wound up, or in circumstances where the Company seeks to buy back its own Shares.

A shareholder of New Shares is entitled to sell or transfer their shares to another person by private agreement or on the ASX, subject to compliance with the Constitution and any applicable laws. In the opinion of the Company there is an established market for Neuren’s ordinary shares on the ASX. Following acceptance for quotation by ASX Limited, the New Shares, like the Existing Shares, may be sold or transferred by the holder at any time on the ASX.

Sales through a broker will attract brokerage at the rates charged by that broker. The Company does not charge fees for registering share transfers.

**Who do I contact with enquiries about my investment?**

Enquiries about this Offer may be made to:

The Chief Financial Officer
Neuren Pharmaceuticals Limited
Level 1, 103 Carlton Gore Road
Newmarket, Auckland
New Zealand

OR BY MAIL TO: PO Box 9923
Newmarket, Auckland
New Zealand

Telephone: 1 800 259 181 (within Australia) or +64 9 529 3940
Fax: +64 9 529 3941
Email: enquiries@neurenpharma.com

Enquiries about your present shareholding can be made to:

Neuren Share Registrar
Link Market Services Limited
Level 9, 333 Collins Street
Melbourne, Victoria 3000
Australia
Telephone: +61 3 9615 9800
Fax: +61 3 9615 9900
Is there anyone to whom I can complain if I have problems with the investment?

Any complaints or problems about this Offer can be made to:

The Chairman
Neuren Pharmaceuticals Limited
Level 1, 103 Carlton Gore Road OR BY MAIL TO: PO Box 9923
Newmarket, Auckland Newmarket, Auckland
New Zealand New Zealand

Telephone: 1 800 259 181 (within Australia) or +64 9 529 3940
Fax: +64 9 529 3941
Email: enquiries@neurenpharma.com

Complaints about the New Shares cannot be made to any Ombudsman in New Zealand.

What other information can I obtain about this investment?

Other information about Neuren and the New Shares is contained or referred to in the remainder of this Letter of Offer, the Constitution, and Neuren’s 2006 Annual Report and 2007 Interim Report, which contain Neuren’s most recent audited financial statements for the year ended 31 December 2006 and unaudited financial statements for the six months ended 30 June 2007 respectively. Copies of the Company’s annual and interim reports and financial statements and this Letter of Offer may be obtained, free of charge, from the Company’s offices in Auckland (New Zealand) as listed in the Company Directory on page 21, or from the Company’s website www.neurenpharma.com.

The Company is listed on ASX and its Existing Shares are quoted on ASX under the code “NEU”. As such, the Company is a ‘disclosing entity’ for the purposes of the Australian Corporations Act and is subject to regular reporting and disclosure obligations, which require it to disclose to ASX any information of which it is or becomes aware concerning the Company and which a reasonable person would expect to have a material effect on the price or value of securities of the Company. Neuren’s financial reports, corporate presentations and announcements may be viewed on the ASX website www.asx.com.au under the security code “NEU”.

All Shareholders on the relevant record dates will be entitled to receive certain information relating to the ongoing performance of the Company in accordance with the Companies Act, the Financial Reporting Act 1993 and the Listing Rules. The Shareholders will either receive this information automatically or will receive notification of their right to request this information. The information includes the Annual Report, containing the Company’s audited financial statements, and the half yearly Interim Report, containing the unaudited half-year financial statements.

The Company will supply Shareholders or prospective investors with the following documents and information on request:

- a copy of this Letter of Offer; and
- a copy of any financial statements of the Company that have been registered under the Financial Reporting Act 1993 (NZ) and that are referred to in this Letter of Offer.

Such requests should be made to the Company in writing at the address specified in the Company Directory on page 21, or can be obtained from its offices as listed in the Company Directory on page 21, or from the Company’s website www.neurenpharma.com. The Constitution is also available on request or from the Company’s website.
Overview

Neuren is an ASX listed company developing drugs for neurological disorders, metabolism and cancer. The drugs target acute indications of brain injury such as cognitive impairment resulting from cardiac surgery and traumatic brain injury, psychiatric symptoms of stroke, as well as progressive neurological conditions such as Alzheimer’s and Parkinson’s diseases. We are currently enrolling patients in a randomized, double-blind, placebo-controlled Phase 3 clinical trial of one of our lead compounds, Glypromate®, to reduce cognitive impairment in patients following cardiac surgery. This trial will involve approximately 600 completed patients across 24 sites in the U.S., Australia and New Zealand. We expect enrolment to be completed by the end of 2008 and results to be available mid-2009. Approximately 70% of patients who have cardiac surgery with cardiopulmonary bypass experience cognitive decline at discharge and up to 35% of patients exhibit cognitive impairment three months after the procedure. With approximately one million cardiac surgery procedures performed annually in the U.S. and other developed countries, including approximately 800,000 coronary artery bypass graft, or CABG, procedures and 200,000 valve repair or replacements using cardiopulmonary bypass, as many as 350,000 patients per year are left with persistent cognitive impairment 1.

We have also recently completed a Phase 1b clinical trial of our second product candidate, NNZ-2566, in an intravenous, or IV, formulation for traumatic brain injury, or TBI. In the U.S., approximately 1.4 million people sustain a TBI resulting in more than 50,000 deaths, 1,100,000 patients treated and released from the emergency room and 235,000 patients hospitalised 2. There presently are no drugs approved for the acute treatment of TBI. The development of NNZ-2566 is being conducted in partnership with the U.S. Army Walter Reed Army Institute of Research.

We are also engaged in preclinical research and development in the treatment of metabolic disorders, such as growth hormone deficiencies, and cancers related to the functions of growth hormone.

On July 31, 2007, we executed a binding term sheet to acquire Hamilton Pharmaceuticals, Inc., a privately-held biopharmaceutical company based in the U.S., whose principal asset is Motiva™, or nefiracetam. The acquisition was completed on 15 October 2007 through the issue of 13,625,443 Neuren Shares. We intend to conduct a Phase 2 clinical trial of Motiva™ as a treatment for post-stroke psychiatric symptoms. Motiva™ has been administered to over 1,700 patients to date in previous Phase 1, 2a and 2b clinical trials in the U.S., Japan and China in which it demonstrated both safety and efficacy. Exclusive, worldwide rights to develop and commercialise Motiva™ were originally licensed by Hamilton from Daiichi Pharmaceutical Co., Ltd., now Daichi Sankyo Co., Ltd., in 2004.

In conjunction with the acquisition of Hamilton, previous shareholders of Hamilton invested US$3.0 million in a convertible note issued by us that will convert into our ordinary shares on the same terms as, and upon consummation of, a capital raising in which Neuren has received subscriptions for, and issued, new ordinary shares in Neuren for an aggregate of at least US$5 million.

Product Candidate Pipeline

Our product candidate pipeline comprises of eight families of compounds across two portfolios, one focused on the central nervous system, or CNS, and the other on growth hormones. Our CNS candidate portfolio is made up of five product families: (i) Glypromate® and NNZ-2566; (ii) Motiva™; (iii) diketopiperazines; (iv) neural regeneration peptides, or NRPs; and (v) macrocyclics. Our growth hormone candidate portfolio is composed of three product families: (i) monoclonal antibodies, or mAbs, against trefoil factors, or TFFs; (ii) human growth hormone variants; and (iii) recently licensed drug discovery and development technology focused on mAbs that target human growth hormone, or hGH, for the potential treatment of cancer.

1 Based on American Heart Association statistics for valve replacement and bypass surgeries in the US in 2004 together with Neuren’s estimate of an equivalent number of surgeries for the rest of the world (developed countries).
2 Brain Injury Association of America.
The following table summarizes our product candidate pipeline. However, there can be no assurance that we will be able to develop, complete development or commercialise any of the following product candidates on a timely basis or at all.

<table>
<thead>
<tr>
<th>Product Candidate</th>
<th>Indication</th>
<th>Stage</th>
<th>Status</th>
<th>Worldwide Commercial Rights</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNS Portfolio</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glypromate®</td>
<td>Cognitive impairment in cardiac surgery patients</td>
<td>Phase 3</td>
<td>Enrolling</td>
<td>Neuren</td>
</tr>
<tr>
<td>NNZ-2566 (IV)</td>
<td>Traumatic brain injury</td>
<td>Phase 1b</td>
<td>Completed</td>
<td>Neuren</td>
</tr>
<tr>
<td>NNZ-2566 (oral)</td>
<td>Traumatic brain injury and stroke recovery</td>
<td>Preclinical</td>
<td>Efficacy testing</td>
<td>Neuren</td>
</tr>
<tr>
<td>Motiva™</td>
<td>Post-stroke depression</td>
<td>Phase 2</td>
<td>Developing protocol</td>
<td>Neuren</td>
</tr>
<tr>
<td>NNZ-2591</td>
<td>Parkinson’s disease and dementia</td>
<td>Preclinical</td>
<td>Efficacy testing</td>
<td>Neuren</td>
</tr>
<tr>
<td>NRPs</td>
<td>Peripheral neuropathy</td>
<td>Preclinical</td>
<td>Lead candidate testing</td>
<td>Neuren / Metabolic Pharmaceuticals</td>
</tr>
<tr>
<td>Macrocyclins</td>
<td>Neurodegenerative diseases</td>
<td>Preclinical</td>
<td>Discovery</td>
<td>Neuren</td>
</tr>
<tr>
<td>Growth Hormone Portfolio</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-TFF mAbs</td>
<td>Oncology</td>
<td>Preclinical</td>
<td>Efficacy testing</td>
<td>Neuren</td>
</tr>
<tr>
<td>hGH variant NNZ-3006</td>
<td>Adult growth hormone deficiency / obesity</td>
<td>Preclinical</td>
<td>Efficacy testing</td>
<td>Neuren</td>
</tr>
<tr>
<td>Anti-hGH mAbs</td>
<td>Oncology</td>
<td>Preclinical</td>
<td>Discovery</td>
<td>Neuren</td>
</tr>
</tbody>
</table>

Milestones and Future Objectives
Since listing on the ASX in January 2005 following the close of our initial public offering, we have accomplished a number of development milestones. These milestones are summarised below, along with some of our key future objectives through 2009. However, there can be no assurance that we will be able to achieve any of the future objectives described below on a timely basis or at all.

2005
- Formed collaboration with Metabolic Pharmaceuticals Limited for the development of NRPs
- Executed Cooperative Research and Development Agreement with the U.S. Army for NNZ-2566 in TBI
- Results from animal models presented by the U.S. Army at the Advanced Technology Applications for Combat Casualty Care conference confirming that NNZ-2566 significantly reduced functional deficits from severe TBI
- Initiated enrolment in our Phase 2a trial of Glypromate® in patients who underwent CABG surgery
- Received two U.S. patents for Glypromate® in Parkinson’s disease
2006

- Announced preclinical results for oral administration of NNZ-2566 indicating significant neuroprotection at various doses
- Initiated a Phase 1a trial of IV administration of NNZ-2566 for TBI in healthy volunteers
- Received U.S. composition of matter and method of use patent for NNZ-2566 in all formulations
- Results from animal models in stroke presented by the U.S. Army at the International Neurotrauma Symposium confirming that NNZ-2566 inhibits non-convulsive seizures
- Completed and announced favourable safety and pharmacokinetic data from our Phase 2a trial of Glypromate® in patients who underwent CAGB surgery
- Announced preclinical results for NNZ-3006, a novel, naturally occurring variant of human growth hormone, demonstrating its ability to reduce fat deposits in two animal models without unwanted side effects
- Announced preclinical results for NNZ-2591, an orally administered diketopiperazine, demonstrating improved performance in a preclinical animal model of learning and memory
- Announced preclinical results for anti-TFF monoclonal antibodies in vitro and for anti-TFF polyclonal antibodies in a xenograft model of breast cancer
- Filed an Investigational New Drug application, or IND, for Glypromate® with the FDA

2007

- Completed and announced favourable safety and tolerability data from the Phase 1a trial of IV administration of NNZ-2566 in healthy volunteers
- Initiated enrolment in our Phase 3 trial of Glypromate® to reduce cognitive impairment in patients following cardiac surgery with cardiopulmonary bypass
- Executed a license agreement with the University of Auckland for a discovery-stage anti-cancer program based on development of antibodies against human growth hormone, or hGH, in hGH-producing cancers
- Initiated enrolment in our Phase 1b trial of NNZ-2566 in healthy volunteers
- Acquired Hamilton Pharmaceuticals, incorporating Motiva™
- Completed and announced favourable safety, tolerability and pharmacokinetic data from our Phase 1b trial of NNZ-2566 in healthy volunteers

Future Objectives³

- Initiate a Phase 2 trial of the IV formulation of NNZ-2566 in mild-to-moderate TBI in mid-2008
- Initiate a Phase 2a trial of the IV formulation of NNZ-2566 in severe TBI in mid-2008
- Data Safety Monitoring Committee to perform interim, unblinded safety analysis of our Phase 3 trial of Glypromate® in mid-2008
- Initiate a Phase 2b trial of Motiva™ in post-stroke psychiatric symptoms in mid-2008
- Complete enrolment in our Phase 3 trial of Glypromate® in late 2008
- Complete and announce results of our Phase 3 trial of Glypromate® in mid-2009
- Complete and announce results of our Phase 2 trial of the IV formulation of NNZ-2566 in mild-to-moderate TBI in mid-2009
- Complete and announce results of our Phase 2a trial of the IV formulation of NNZ-2566 in severe TBI in mid-2009
- Complete and announce results of our Phase 2 trial of Motiva™ in post-stroke psychiatric symptoms in mid-2009

³ The successful completion of this Offer, together with further capital raising, joint venture and licensing opportunities are necessary to fund all of the future objectives noted.
PURPOSE AND EFFECT OF THE OFFER

Purpose of the Offer and Use of Proceeds

Neuren has a number of initiatives underway both locally (Australia and New Zealand) and internationally to raise further capital for the Company through the issue of securities to new investors. The Company is also actively pursuing a number of licensing and/or joint venture initiatives to assist in the funding required to take its pipeline of lead compounds through the next stage of clinical trials. The Directors have decided that until such funding is available, the primary focus of the Company should be the completion of the current Phase 3 Glypromate® trial and that this should be funded through this Offer.

If the Offer proceeds as contemplated and is fully subscribed, the total capital raise of A$10.1 million (gross) will support completion of the first Glypromate® Phase 3 trial as well as associated overhead and corporate operating expenses. The underwritten amount of A$7.1 million which is the minimum that will be raised under this Offer will trigger conversion of the outstanding convertible notes held by the former Hamilton Pharmaceuticals shareholders, will support Glypromate® clinical trial costs and overhead through 2008 and will allow other capital raising, joint venture and licensing opportunities currently underway to be pursued.

As this Offer is partially underwritten, the Directors have not established a minimum amount which must be raised before the Directors will accept subscriptions and allot New Shares under this Offer.

Capital Structure

The following table shows the number of Existing Shares at the date of the Offer and the total number of issued Shares at the close of the Offer assuming the Offer is fully subscribed.

<table>
<thead>
<tr>
<th>Ordinary Shares</th>
</tr>
</thead>
<tbody>
<tr>
<td>Existing Shares at the date of this Letter of Offer</td>
</tr>
<tr>
<td>Total New Shares offered</td>
</tr>
<tr>
<td>Total issued Shares on Close of the Offer (if fully subscribed)</td>
</tr>
</tbody>
</table>

The above table assumes that no Options are exercised prior to the Record Date. These figures, and the total issued Shares on Close of the Offer are necessarily approximate as individual Entitlements will be rounded down when calculating entitlements. There are 20,637,627 issued options over Neuren Shares at the date of the Offer exercisable at prices ranging from NZ$0.392 (approximately A$0.35) to A$0.60 per share with expiry dates ranging from December 2008 to March 2010. The options do not entitle the holder to participate in the Offer.

In addition, the minimum amount to be raised under this Offer, being the underwritten amount of A$7.1 million, will (on acceptance of subscriptions of that amount) result in the conversion at A$0.14 per Share of the convertible notes previously issued by Neuren with a principal amount of US$3 million. The number of Shares to be issued on conversion of the convertible notes will depend on the exact Australian dollar to United States dollar exchange rate on conversion, however approximately 25.4 million Shares are expected to be issued on conversion.

Underwriting arrangements – effect on capital structure and control

Of the A$10.1 million sought to be raised under the Offer (before the costs of the Offer), the Offer is underwritten to A$7.1 million.

This means that, for example, if Shareholders take up their Entitlements or subscribe for additional New Shares in the Shortfall up to A$5 million, the Underwriter will subscribe for the balance of A$2.1 million, raising a total of A$7.1 million. Similarly if, for example, Shareholders take up their Entitlements or subscribe for additional New Shares in the Shortfall up to A$500,000, the Underwriter will subscribe for A$6.6 million, raising a total of A$7.1 million.
If the Offer is fully subscribed (whether through take up of Entitlements, Shortfall and/or underwriting), it will result in the issue of approximately 72.4 million New Shares, raising approximately A$10.1 million.

The issue of New Shares under the Offer is not expected to have any effect on the control of the Company.

**ISSUE EXPENSES**

The total expenses of the issue payable by the Company, including all legal costs, accounting fees, printing costs, share registry and other costs, are estimated to be A$26,500 plus GST, excluding the underwriting and management fee which will be A$425,880 plus GST (if applicable), and the 3,000,000 A$0.25 options over ordinary shares, with a three year term, to be granted to the Underwriter on completion of the Offer.

A Shareholder in which Mr Trevor Scott, a director of the Company, has an interest has agreed to sub-underwrite the Offer for up to 6,570,000 New Shares, for which it will receive a sub-underwriting commission of 2.5% of the amount ultimately sub-underwritten. This sub-underwriting fee is to be paid by the Underwriter from its fees noted above.

No brokerage is payable by any Shareholder subscribing for New Shares comprising their Entitlement. The Company may at its discretion pay a commission on a Shortfall Application received, in particular in respect of applications bearing a broker stamp at the rate of between 2.5% and 5.0%, provided the Shortfall Application is accepted by the Directors and New Shares are subsequently allotted. The payment of any commission will be made 14 days after acceptance by the Company of a Shortfall Application.

**DESCRIPTION OF SHARES**

The Shares are fully paid ordinary shares and are all of the same class and rank equally in every respect. Set out below is a summary of some of the principal rights of Shareholders pursuant to the Constitution. It does not purport to constitute an exhaustive or definitive statement of the rights and liabilities of the Shareholders. Investors are accordingly encouraged to inspect the Constitution.

The rights and liabilities attaching to the Shares are also regulated by the New Zealand Companies Act, the general law and the Listing Rules of the ASX.

**Meetings of Shareholders**

Each Shareholder is entitled to receive a notice of and attend and vote at general meetings of the Company and to receive all notices, reports and financial statements required to be sent to Shareholders under the Constitution, the Companies Act, the Listing Rules or other requirements.

The Company may serve a notice on the Shareholder either personally, by sending it by post addressed to the Shareholder’s registered address or to the Shareholder’s email address.

**Voting Rights**

At a general meeting, subject to any special privileges or restrictions as to voting for the time being attached to any special class of shares, on a show of hands every Shareholder present in person or by proxy has one vote. On a poll, each Shareholder present in person or by proxy will have one vote for every Share which that Shareholder holds or represents. No Shareholder will be entitled, in respect of Shares held by that Shareholder, to exercise voting rights or to form part of any quorum by virtue of his or her holding such Shares if any call or other sum presently payable by that member to the Company in respect of such Shares remains unpaid.
Subject to the Companies Act, the general law and the Listing Rules, in the case of equality of votes, whether on a show of hands by voice or on a poll, the Chairman of that Shareholders’ meeting is not entitled to a second or casting vote.

**Dividend Rights**
The Directors, in accordance with the Companies Act, may declare dividends.

Unless and to the extent that the rights attached to any shares or the terms of issue thereof otherwise provide, all dividends will (as regards any Shares not fully paid throughout the period in respect of which the dividend is paid) be apportioned and paid pro rata according to the amount paid on the Shares during any portion or portions of the period in respect of which the dividend is paid. For this purpose, no amount paid on a Share in advance of calls will be treated as paid on the share.

**Transfer of Shares**
Shares may be transferred electronically (by an electronic transfer system approved by any statute of New Zealand) or by instrument in a form as approved by the Directors and any stock exchange upon which the Company may be listed.

There will be no restriction on the transfer of Shares except where:
- required by law, the listing rules of any stock exchange upon which the Shares may be listed; or
- where the Board in its discretion granted by the Constitution refuses to transfer the Shares.

**Issue of Further Shares**
Subject to the Companies Act, the Listing Rules and any special rights previously conferred on the holders of any existing shares or class of shares, the Directors may issue shares at any time without the prior approval of the Company in a general meeting, to any persons on such terms and conditions and for such consideration and at such time and on such payment terms as the Directors may think fit.

Any shares may be issued in such denomination or with such preferential, deferred, qualified or special rights, privileges, conditions or restrictions or limitations including as to distributions, voting rights and ranking as the Directors may think fit.

**Variation of Rights**
The issue of shares ranking equally with or in priority to any existing shares will not affect the rights of the existing shares unless specifically provided for in the terms of issue of those existing shares.

**Winding Up**
If the Company is wound up (whether the liquidation is voluntary, under supervision, or by the court) the liquidator may, with the authority of a special resolution or any other sanction required by the Companies Act, divide among the members in kind the whole or any part of the assets of the Company and whether or not the assets will consist of property of the same or different kinds, and may for such purpose set such value as the liquidator deems fair upon any of the property to be divided as aforesaid and may determine how such division will be carried out as between the members or different classes of members.

The liquidator may, with the approval of the Company by special resolution, vest the whole or any part of the assets in trustees upon such trusts for the benefit of members as the liquidator with the approval of the Company by special resolution will think fit, and the Company dissolved, but so that no contributory will be compelled to accept any shares or other property in respect of which there is a liability.
Share Buy Backs
The Company may buy Shares in itself on the terms and at the times determined by the Board, to extent and in the manner permitted by the listing rules of any stock exchange upon which the shares of the Company may be listed and the Companies Act.

Compliance with ASX Listing Rules
The Constitution was amended on 4 October 2004 to incorporate Appendix 15A of the Listing Rules of the ASX. Accordingly, the following applies:

- Notwithstanding anything contained in the Constitution, if the Listing Rules prohibit an act being done, the act shall not be done.
- Nothing contained in the Constitution prevents an act being done that the Listing Rules require to be done.
- If the Listing Rules require an act to be done or not to be done, authority is given for that act to be done or not to be done (as the case may be).
- If the Listing Rules require the Constitution to contain a provision and it does not contain such a provision, the Constitution is deemed to contain that provision.
- If the Listing Rules require the Constitution not to contain a provision and it contains such a provision the Constitution is deemed not to contain that provision.
- If any provision of the Constitution is or becomes inconsistent with the Listing Rules, the Constitution is deemed not to contain that provision to the extent of the inconsistency.

Alteration of Constitution
The Constitution can only be amended by a special resolution passed by at least 75% of the votes cast by Shareholders present and voting at the general meeting. At least 10 business days’ written notice specifying the intention to propose the resolution as a special resolution must be given.

Number of Directors
The number of Directors, other than alternate directors, will not be less than 3 or more than 9 or such other number as is fixed by an ordinary resolution of the Company. At least 2 Directors of the Company must be ordinarily resident in New Zealand.

Appointment and Removal of Directors
Subject to the Constitution, the Board or the Company by ordinary resolution may appoint any person as a Director either to fill a casual vacancy or as an additional Director.

The Listing Rules require that the Company hold an election of Directors by ordinary resolution each year. The Directors, other than a managing director, must not hold office (without re-election) past the third annual meeting of Shareholders following the Director’s appointment or 3 years, whichever is longer. However, a Director appointed to fill a casual vacancy or as an addition to the Board must not hold office (without re-election) past the next annual meeting of Shareholders.

The Company may by ordinary resolution, subject to the Constitution, from time to time remove any Director before the expiration of his or her period of office and appoint another person in their place.
COMPANY DIRECTORY

Directors
Dr Robin Congreve
Mr Tom Amos
Dr Graeme Howie
Mr Trevor Scott
Dr Douglas Wilson

Broker and Underwriter to the Offer
Taylor Collison Limited
Level 10, 167 Macquarie Street
Sydney NSW 2000
Tel: +61 2 9232 1688

Company Secretary
Mr Robert Waring

Auditor
PricewaterhouseCoopers
188 Quay Street
Private Bag 92162
Auckland, New Zealand

NZ Registered and Corporate Head Office
Level 1
103 Carlton Gore Road
Newmarket, Auckland
New Zealand
Tel: +64 9 529 3940
Fax: +64 9 529 3941

Share Registrar
Link Market Services Limited
Level 9, 333 Collins Street
Melbourne, Victoria 3000
Australia
Tel: +61 3 9615 9800
Fax: +61 3 9615 9900

Australian Registered Office
Level 13
122 Arthur Street
North Sydney NSW 2060
Tel: +61 2 9956 8500
# DEFINITIONS AND INTERPRETATIONS

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>NZ$</td>
<td>refers to New Zealand dollars</td>
</tr>
<tr>
<td>A$</td>
<td>refers to Australian dollars</td>
</tr>
<tr>
<td>Application Form</td>
<td>the combined Entitlement &amp; Acceptance and Shortfall Application Form that accompanies this Letter of Offer for Eligible Shareholders as at the Record Date.</td>
</tr>
<tr>
<td>Application Monies</td>
<td>the total monies payable by an applicant at the time of subscribing for a specified number of the New Shares</td>
</tr>
<tr>
<td>ASX</td>
<td>ASX Limited or the Australian Securities Exchange that it operates (as the context requires).</td>
</tr>
<tr>
<td>Board</td>
<td>the board of Directors of the Company</td>
</tr>
<tr>
<td>Close or Closing Date</td>
<td>the date so described in the table on page 1 of this Letter of Offer</td>
</tr>
<tr>
<td>Companies Act</td>
<td>the New Zealand Companies Act 1993</td>
</tr>
<tr>
<td>Company or Neuren</td>
<td>Neuren Pharmaceuticals Limited (New Zealand Registered Company Number AK1181152; Australian Registered Body Number 111 496 130), including its subsidiaries.</td>
</tr>
<tr>
<td>Constitution</td>
<td>the constitution of the Company as amended from time to time.</td>
</tr>
<tr>
<td>Corporations Act</td>
<td>the Australian Corporations Act 2001 (Cth)</td>
</tr>
<tr>
<td>Director</td>
<td>a director of the Company</td>
</tr>
<tr>
<td>Eligible Shareholders</td>
<td>means those Shareholders which the Company considers eligible to participate in the Offer, including without limitation: (a) all Shareholders with registered addresses in Australia; and (b) all Shareholders whose registered address is in New Zealand, and Eligible Shareholder means any one of those Shareholders.</td>
</tr>
<tr>
<td>Entitlement</td>
<td>the number of New Shares to which a Shareholder with a registered address in New Zealand or Australia at 5 p.m. (AEST) on the Record Date is entitled to apply for under this Offer and as set out in the Application Form</td>
</tr>
<tr>
<td>Existing Share</td>
<td>a fully paid ordinary share in the Company on issue at 7 p.m. (AEST) on the Record Date</td>
</tr>
<tr>
<td>Letter of Offer or LOO</td>
<td>this Letter of Offer dated 19 December 2007</td>
</tr>
<tr>
<td>Listing Rules</td>
<td>the listing rules of the ASX as amended from time to time and for so long as the Company is admitted to the official list of the ASX</td>
</tr>
<tr>
<td>New Shares</td>
<td>up to 72,369,626 new ordinary shares in the Company offered to New Zealand and Australian resident shareholders pursuant to the Offer</td>
</tr>
<tr>
<td>Offer</td>
<td>this offer of New Shares made by the Company as set out in this Letter of Offer</td>
</tr>
<tr>
<td>Record Date</td>
<td>7 p.m. (AEST) on 2 January 2008</td>
</tr>
<tr>
<td>Share</td>
<td>one ordinary fully paid share in the Company, be it an Existing Share or a New Share</td>
</tr>
<tr>
<td>Shareholder</td>
<td>a holder of Existing Shares in the Company</td>
</tr>
<tr>
<td>Shortfall</td>
<td>the total New Shares from Entitlements not accepted by Shareholders under this Offer</td>
</tr>
<tr>
<td>Shortfall Application</td>
<td>an application for an allocation of New Shares, in excess of the Entitlement, from the Shortfall</td>
</tr>
<tr>
<td>Underwriter</td>
<td>Taylor Collison Limited (ACN 008 172 450)</td>
</tr>
</tbody>
</table>
For a 1 for 2 non-renounceable rights issue by Neuren Pharmaceuticals Limited to existing New Zealand and Australian resident Shareholders of 72,369,626 ordinary shares.

Record date: 2 January 2008

This is an important document and you should read it carefully. If you have any queries or concerns you should contact the Company or your own legal or financial advisor.
IMPORTANT INFORMATION
(The information in this section is required under the Securities Act 1978)

Investment decisions are very important. They often have long-term consequences. Read all documents carefully. Ask questions. Seek advice before committing yourself.

Choosing an investment

When deciding to invest, consider carefully the answers to the following questions that can be found on the pages noted below:

What sort of investment is this? ......................................................................................................................................6
Who is involved in providing it for me? ..................................................................................................................7
How much do I pay? .......................................................................................................................................................8
What are the charges?..................................................................................................................................................10
What returns will I get? .................................................................................................................................................10
What are my risks? ........................................................................................................................................................11
Can the investment be altered? ....................................................................................................................................13
How do I cash in my investment? .................................................................................................................................13
Who do I contact with enquiries about my investment? ..............................................................................................13
Is there anyone to whom I can complain if I have problems with the investment? .........................................................14
What other information can I obtain about this investment? ........................................................................................14

In addition to the information in this Investment Statement, important information can be found in the Prospectus to which this Investment Statement relates and which is set out on pages 2 to 5 and 15 to 24 of this Investment Statement and Prospectus.

Choosing an investment adviser

You have the right to request from any investment adviser a written disclosure statement stating his or her experience and qualifications to give advice. The document will tell you:

- whether the adviser gives advice only about particular types of investments; and
- whether the advice is limited to the investments offered by one or more particular financial organisations; and
- whether the adviser will receive a commission or other benefit from advising you.

You are strongly encouraged to request that statement. An investment adviser commits an offence if he or she does not provide you with a written disclosure statement within five working days of your request. You must make the request at the time the advice is given or within one month of receiving the advice.

In addition:

- if an investment adviser has any conviction for dishonesty or has been adjudged bankrupt, he or she must tell you this in writing; and
- if an investment adviser receives any money or assets on your behalf, he or she must tell you in writing the methods employed for this purpose.

Tell the adviser what the purpose of your investment is. This is important because different investments are suitable for different purposes.
CONTENTS

CHAIRMAN’S LETTER .....................................................................................................................................................3
SUMMARY OF OFFER ....................................................................................................................................................4
INVESTMENT STATEMENT ..............................................................................................................................................6
MAIN TERMS OF OFFER ..............................................................................................................................................15
PROSPECTS .................................................................................................................................................................15
ISSUE EXPENSES ..........................................................................................................................................................18
OTHER TERMS OF OFFER AND SECURITIES ..............................................................................................................18
DESCRIPTION OF SHARES ...........................................................................................................................................19
DIRECTORS’ STATEMENT .............................................................................................................................................22
COMPANY DIRECTORY ................................................................................................................................................23
DEFINITIONS AND INTERPRETATIONS ..........................................................................................................................24
INTERIM FINANCIAL STATEMENTS ..............................................................................................................................24

IMPORTANT DATES

Announcement of Rights Issue 19 December 2007
Lodgement Date – Investment Statement and Prospectus, ASX Appendix 3B and cleansing notice lodged with ASX 19 December 2007
Record Date for calculation of Entitlements (9.00 pm New Zealand time) 2 January 2008
Investment Statement and Prospectus, including Application Form, sent to Shareholders 8 January 2008
Closing Date for receipt of acceptances, at 5 p.m. New Zealand time 25 January 2008
Shortfall Notification Date 31 January 2008
Allotment of New Shares 1 February 2008
Expected despatch of statement of holdings for New Shares Not later than 5 February 2008

DEFINED TERMS

Words defined in the glossary “Definitions and Interpretations” at the end of this Investment Statement and Prospectus are used in this Investment Statement and Prospectus with an initial capital letter.
Dear Shareholder,

Neuren is making this pro-rata rights issue offer of up to 72,369,626 new ordinary shares to its New Zealand and Australian resident Shareholders, at NZ$0.16 per New Share for New Zealand resident Shareholders (based on an exchange rate fixed by Neuren of NZ$1.00 equals $0.8750 Australian dollars) and A$0.14 per New Share for Australian resident Shareholders. New Zealand resident Shareholders may alternatively pay A$0.14 per New Share by subscribing in Australian dollars. This Offer is partially underwritten to A$7.1 million by Taylor Collison Limited.

Approximately 26,700,000 of the New Shares are being offered to New Zealand resident Shareholders, and this Investment Statement and Prospectus is required under New Zealand securities laws in order to make the Offer to New Zealand resident Shareholders. The exact number of New Shares being offered to New Zealand resident Shareholders will be determined on the Record Date based on the offer ratio of one New Share for every two existing Shares held by New Zealand resident Shareholders. Neuren is taking advantage of exemptions under Australian securities laws which mean that a prospectus or disclosure document is not required in Australia for the purpose of making the Offer to Australian resident Shareholders. However the terms of the Offer are the same for all Shareholders in Australia and New Zealand, including being able to apply for additional shares under the Shortfall described on page 7.

Your Entitlement to New Shares is set out in the enclosed Application Form, and instructions on how to apply for your Entitlement, and should you wish, additional New Shares in excess of your Entitlement from the Shortfall, are set out in the Investment Statement on pages 6 to 15.

Neuren is making good progress with all of its product candidates. We have a robust product portfolio focused on psychiatric and cognitive effects of neurological injury and disease. Three of our drugs are in clinical trials for four central nervous system indications, with efficacy results expected in 2009. Following these, Neuren potentially only has to conduct 1 or 2 more pivotal trials to make a new drug application to be able to market each drug. We also have a strong preclinical pipeline in neurology, cancer and metabolic diseases presenting significant partnership and/or licensing opportunities for which we are currently in discussions.

Further details on the status of our pipeline are set out in the “Prospects” section on pages 15 to 18.

The capital raised in a fully subscribed Offer of A$10.1 million (gross) will support completion of the first Glypromate® Phase 3 trial as well as associated overhead and corporate operating expenses. The underwritten amount of A$7.1 million which is the minimum that will be raised under this Offer will trigger conversion of the outstanding convertible notes held by the former Hamilton Pharmaceuticals shareholders, will support Glypromate® clinical trial costs and overhead through 2008 and will allow other capital raising, joint venture and licensing opportunities currently underway to be pursued.

The Board recommends this Offer to you and thanks Shareholders for their continued support of the Company.

Yours sincerely

Chairman
SUMMARY OF OFFER

Introduction

Neuren Pharmaceuticals Limited ("Neuren" or the "Company") is offering 72,369,626 ordinary shares to the registered New Zealand and Australian resident holders of ordinary shares in the Company as at 2 January 2008 in the ratio of one new ordinary share for every two ordinary shares held at that date, at a price of NZ$0.16 per New Share to New Zealand resident Shareholders (based on an exchange rate fixed by Neuren of NZ$1.00 equals $0.8750 Australian dollars) and A$0.14 per New Share to Australian resident Shareholders, payable on application (this "Offer"). New Zealand resident Shareholders may alternatively pay A$0.14 per New Share by subscribing in Australian dollars. Assuming this Offer is fully subscribed, the New Shares will represent 33.3% of Neuren's issued ordinary shares after allotment of the New Shares. Your Entitlement to be issued New Shares under this Offer is not renounceable – i.e., it may not be sold or otherwise transferred.

This Investment Statement and Prospectus has been prepared in compliance with New Zealand securities laws for the purpose of making the Offer to New Zealand resident Shareholders only.

The New Shares will rank equally in all respects with the Company’s Existing Shares. The Offer may be accepted in full or in part and there is no minimum level of Entitlement that must be accepted by a Shareholder in order to participate in the Offer. Shareholders can apply, in the “Shortfall Application” section of the Application Form, for New Shares in excess of their Entitlement that have not been taken up by other Shareholders.

The Offer is partially underwritten by Taylor Collison Limited (ACN 008 172 450) for up to 50,700,000 New Shares.

An application will constitute an irrevocable offer by the applicant to acquire the number of New Shares specified in the application. If the full amount of the subscription monies payable for the New Shares subscribed for (the “Application Monies”) is not paid on application or a cheque does not clear, an application may be rejected or an allocation cancelled.

As this Offer is partially underwritten, the Directors have not established a minimum amount which must be raised before the Directors will accept subscriptions and allot New Shares under this Offer.

Instructions on how to apply for the New Shares are set out under the headings “How much do I pay?” on pages 8 to 10 and on the Application Form itself.

Registration

This Investment Statement and Prospectus is dated 19 December 2007.

A copy of this Investment Statement and Prospectus signed by the Directors of Neuren Pharmaceuticals Limited and having endorsed or attached all documents, information, certificates and other matters required to be so endorsed or attached by section 41 of the Securities Act 1978 has been delivered to the Registrar of Companies at Auckland, for registration under section 42 of the Securities Act 1978 and regulation 4 of the Securities Regulations 1983. Such documents include Neuren’s 2006 Annual Report (which contains the most recent audited financial statements of Neuren for the year ended 31 December 2006) and unaudited interim financial statements for the six months ended 30 June 2007. The Registrar of Companies accepts no responsibility for any statement in this Investment Statement and Prospectus.

No Overseas Offers

This Investment Statement and Prospectus does not constitute an offer in any jurisdiction in which, or to any person to whom, it would be unlawful to make such an offer. Where this Investment Statement and Prospectus has been despatched to investors domiciled outside New Zealand and where that country’s securities code and legislation requires registration, this Investment Statement and Prospectus is provided for information purposes only. Non resident investors should consult their
professional advisers as to whether any governmental or other consents are required or whether formalities need to be observed to enable them to participate in the Shortfall.

The Company is of the view that it is unreasonable to make the Offer to shareholders outside of Australia and New Zealand having regard to:

- the number of Shareholders outside of Australia and New Zealand;
- the number and value of the securities that could be offered to Shareholders outside of Australia and New Zealand; and
- the cost of complying with the legal requirements and requirements of regulatory authorities in the overseas jurisdictions.

Accordingly, the Company is not required to make the Offer to Shareholders outside of Australia and New Zealand (though this Investment Statement and Prospectus may be sent to Shareholders outside these jurisdictions for information purposes only).

Stock Exchange Listing

Application has been made to ASX for permission to list the securities and all the requirements of ASX relating thereto that can be complied with on or before the date of this Investment Statement and Prospectus have been duly complied with. However, ASX accepts no responsibility for any statement in this Investment Statement and Prospectus. If the ASX does not grant permission for quotation of the New Shares offered pursuant to this Investment Statement and Prospectus within three (3) months after the date of this Investment Statement and Prospectus, or such longer period as is permitted, none of the New Shares offered by this Investment Statement and Prospectus will be allotted or issued. In these circumstances, the Company will repay all application monies, without interest.

The Company will not seek listing of the New Shares on the New Zealand Stock Exchange.

Statutory Index

As required by Regulation 4 and 5(6) of the New Zealand Securities Regulations 1983, the matters required to be stated or contained in this Investment Statement and Prospectus by the First Schedule of the Securities Regulations 1983 are:

<table>
<thead>
<tr>
<th>First Schedule Clause Ref.</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Main Terms of the Offer</td>
<td>6 – 8</td>
</tr>
<tr>
<td>9 Prospects</td>
<td>3, 15 – 18</td>
</tr>
<tr>
<td>19(1) Issue Expenses</td>
<td>18</td>
</tr>
<tr>
<td>21 Other Terms of Offer and Securities</td>
<td>19</td>
</tr>
</tbody>
</table>
INVESTMENT STATEMENT

This Investment Statement set out on pages 1, and 6 to 15 of this offer document is dated 19 December 2007 and is an Investment Statement for the purposes of the Securities Act 1978 and the Securities Regulations 1983. The Prospectus to which this Investment Statement relates forms part of this offer document and is set out on pages 2 to 5, and 15 to 24.

What sort of investment is this?

Offer
This is an offer by Neuren of a maximum of 72,369,626 ordinary shares to the New Zealand and Australian resident registered holders of ordinary shares in the Company as at 2 January 2008 in the ratio of one new ordinary share for every two ordinary shares held at that date, at a price of NZ$0.16 per New Share to New Zealand resident Shareholders (based on an exchange rate fixed by Neuren of NZ$1.00 equals $0.8750 Australian dollars) and A$0.14 per New Share to Australian resident Shareholders, payable on application. New Zealand resident Shareholders may alternatively pay A$0.14 per New Share by subscribing in Australian dollars. Assuming this Offer is fully subscribed, the New Shares will represent 33.3% of Neuren’s issued ordinary shares after allotment of the New Shares. Your Entitlement to be issued New Shares under this Offer is not renounceable – i.e, it may not be sold or otherwise transferred.

To the extent that there is a Shortfall, you may apply for additional New Shares (over and above your Entitlement) by a Shortfall Application. Acceptance of Shortfall Applications will be considered by the Company in its sole discretion.

Except for applications in respect of the Shortfall, registered holders of ordinary shares may not apply for New Shares in excess of the Entitlement. Application Monies for New Shares in excess of Entitlements will be refunded without interest. Refunds will be posted within seven calendar days of allotment of the New Shares.

New Shares
Each New Share issued shall rank equally in all respects with the Existing Shares in the Company at the time of issue and will provide you with the right to:

- an equal share with other ordinary shares in the Company in dividends, if any, authorised by the Board;
- attend and vote at meetings of the Company, including the right to cast one vote on a poll held at such meetings;
- receive certain Company information;
- an equal share with other ordinary shares in the Company in the distribution of any surplus assets on liquidation of the Company; and
- other rights conferred on shareholders by the Constitution and the Companies Act.

The Constitution may be viewed during normal business hours at the Registered Office of the Company (the address of which is set out on page 8) or online at the website of the Company (www.neurenpharma.com), the Registrar of Companies (www.companies.govt.nz), or the ASX (www.asx.au.com).

See the section entitled “Description of Shares” on pages 19 to 21 for further information relating to the New Shares.

Application has been made to ASX for permission to list the securities and all the requirements of ASX relating thereto that can be complied with on or before the date of this Investment Statement and Prospectus have been duly complied with. However, ASX accepts no responsibility for any statement in this Investment Statement and Prospectus. If the ASX does not grant permission for quotation of the New Shares offered pursuant to this Investment Statement and Prospectus within three (3) months after the date of this Prospectus, or such longer period as is permitted, none of the New Shares offered by this Prospectus will be allotted or issued. In these circumstances, the Company will repay all application monies, without interest.
Shortfall

The Directors reserve the right, by no later than 25 April 2008, to place any New Shares which are not taken up by holders of Existing Shares under this Offer, or which because of fractional Entitlements are not otherwise offered, to such persons and in such manner as the Directors consider equitable and in the interests of the Company, provided that the New Shares offered under the Shortfall are issued at not less than the price under the Offer and the terms and conditions of the issue of such New Shares are not materially more favourable to the persons to whom they are issued than the terms of this Offer.

An application to participate in any Shortfall may be made pursuant to this Investment Statement and Prospectus by a Shareholder in New Zealand, although other persons may apply for the Shortfall to the extent permitted by relevant securities laws, provided that the Directors may not participate in any Shortfall.

The Directors will allocate any Shortfall in such manner as the Directors consider equitable and in the interests of the Company. The Directors do not guarantee that any Shortfall Application will be successful. In the event a Shortfall Application is not accepted (whether in whole or in part) monies in relation to the New Shares applied for and not allocated will be refunded in full without interest within 7 days of notification of the Shortfall by the Company to ASX.

The Company may at its discretion pay a commission on a Shortfall Application received, in particular in respect of applications bearing a broker stamp of a member organisation of the ASX, provided the Shortfall Application is accepted by the Directors and New Shares are subsequently allotted. The payment of any commission will be made 14 days after acceptance by the Company of a Shortfall Application.

It should also be noted that the Company has entered into an agreement in respect of the underwriting of part of the Shortfall, as described in more detail under the heading "Underwriting" below.

Underwriting

The Offer is partially underwritten by Taylor Collison Limited (ACN 008 172 450) (the "Underwriter") pursuant to an agreement between the Underwriter and the Company dated 19 December 2007. The terms of the underwrite are such that the Company may call upon the Underwriter to subscribe for, or cause the subscription for, 50,700,000 New Shares less the number of New Shares subscribed for under this Offer (including subscriptions for the Shortfall). By way of example, if subscriptions were received and accepted for 10,000,000 New Shares, the Company could call upon the Underwriter to subscribe, or cause the subscription, for 40,700,000 New Shares. If subscriptions were received in respect of 50,700,000 or more New Shares, the Company could not call upon the Underwriter to subscribe for New Shares.

A Shareholder with which Mr Trevor Scott, a director of the Company, has an association has agreed to sub-underwrite the Offer for up to 6,570,000 New Shares.

Details of the underwriting fee payable to the Underwriter are set out on page 10, under the heading "What are the charges?".

Other terms

All other terms of this Offer and the New Shares are contained in this Investment Statement and Prospectus, with the exception of those rights and obligations implied by law or set out in the Company’s Constitution.

Who is involved in providing it for me?

Names and addresses

Issuer

The issuer of the New Shares that are subject to this Investment Statement and Prospectus is Neuren Pharmaceuticals Limited (NZ registered company number 1181152; ARBN 111 496 130).
Activities

Neuren, which was incorporated on 17 December 2001, is developing drugs for neurological disorders, metabolism and cancer. The drugs target acute indications of brain injury such as cognitive impairment resulting from cardiac surgery and traumatic brain injury, psychiatric symptoms of stroke, as well as chronic conditions such as Parkinson’s and Alzheimer’s diseases.

Neuren has four lead candidates; Glypromate®, Motiva™ and NNZ-2566 presently in clinical development to treat four different neurological conditions, and NNZ-2591 in preclinical development for Parkinson’s disease dementia and other chronic neurodegenerative conditions.

Neuren has operations in New Zealand (Auckland based head office), Australia and the United States, and is listed on the Australian Securities Exchange (ASX: NEU).

The principal activities of the Company are described in more detail in the section of this Investment Statement and Prospectus entitled “Prospects” on pages 15 to 18.

No person or entity guarantees the securities offered in this Investment Statement and Prospectus.

How much do I pay?

Share Price

You must apply for a specific number of New Shares and you must pay the full subscription price on application. The New Zealand dollar subscription price is NZ$0.16 per Share for New Zealand resident investors (based on an exchange rate fixed by Neuren of NZ$1.00 equals $0.8750 Australian dollars). New Zealand resident Shareholders may alternatively pay A$0.14 per New Share and subscribe in Australian dollars.

Acceptance of the Offer

The number of New Shares to which you are entitled is set out in the Application Form accompanying this Investment Statement and Prospectus. The number of New Shares to which shareholders are entitled will, in the case of fractional Entitlements, be rounded down to the nearest whole number. Your rights to subscribe for New Shares are not renounceable.

This Offer may be accepted in full or in part and there is no minimum level of Entitlement that must be accepted by a Shareholder in order to participate in the Offer. Shareholders can apply, on the Application Form, for an allocation of New Shares in excess of their Entitlement from the Shortfall.

Applications for New Shares must be made so as to be received no later than 5 p.m. (New Zealand time) on Friday 25 January 2008 (“Closing Date”). The Directors reserve the right to extend the Closing Date.

To subscribe for a certain number of New Shares, you must send the total subscription payable for those New Shares (the “Application Monies”), together with a completed Application Form (accompanying this Investment Statement and Prospectus), to Neuren.

Any Application Monies paid by you for New Shares will be held on trust for you until the Company effects the issue to you of the relevant number of New Shares, at which time the relevant funds will be released beneficially to the Company.
Listed below are the steps to be taken if you wish to:

- accept your Entitlement in full or in part; or
- apply for additional New Shares to be allocated from the Shortfall.

**To accept all or part of your Entitlement**

Complete and sign the Entitlement & Acceptance section of the Application Form specifying the number of New Shares comprising your Entitlement you wish to accept) and send the Application Form and a cheque (or bank draft if paying in Australian dollars) made payable to: “Neuren Pharmaceuticals Limited Trust Account” and crossed “Not Transferable”. All cheques must be in New Zealand dollars and sent with the completed Application Form to:

The Share Offer  
Neuren Pharmaceuticals Limited  
PO Box 9923  
Newmarket  
Auckland

**To apply for additional New Shares**

If applicants wish to participate in any Shortfall that may arise under this Offer, they should complete the Shortfall Application section of the Application Form attached to this Investment Statement and Prospectus. The completed Application Form together with a cheque (or bank draft if paying in Australian dollars) made payable to “Neuren Pharmaceuticals Limited Trust Account” and crossed “Not Transferable” should be sent before the Closing Date to:

The Share Offer  
Neuren Pharmaceuticals Limited  
PO Box 9923  
Newmarket  
Auckland

The Directors will allocate any Shortfall in such manner as the Directors consider equitable and in the interests of the Company. The Directors do not guarantee that any Shortfall Application will be successful. In the event the Shortfall Application is not accepted (whether in whole or in part) monies in relation to the New Shares applied for and not allocated will be refunded in full without interest within 7 days of notification of the Shortfall by the Company to ASX.

The completed Application Form must be received not later than 5.00 p.m. (New Zealand time) on 25 January 2008 (or such later closing date as determined by the Company).

Please note that if you do not accept all or part of your Entitlement in accordance with the instructions set out above, any Entitlement not accepted will form part of the Shortfall.

Please also note that post-dated cheques will not be accepted. If the full amount of the Application Monies is not paid upon application or a cheque does not clear, your application may be rejected or any allocation of New Shares made to you may be cancelled.

An application will constitute an irrevocable offer by you to acquire the number of New Shares specified, on the terms and conditions set out in this Investment Statement and Prospectus and the Application Form. By submitting an application you agree to be bound by these terms and conditions and the Constitution. Applications cannot be revoked or withdrawn and Application Monies (except in the case of Entitlement over-subscription or applications to participate in the Shortfall that are not accepted by the Company) will not, therefore, be refunded. As indicated above, you should note that the Company reserves the right to extend the Offer and that such extension may result in the dates referred to in the table on page 2 of this Investment Statement and Prospectus being altered. Any such changes will be advised through the ASX companies announcements platform.
As this Offer is partially underwritten, the Directors have not established a minimum amount which must be raised before the Directors will accept subscriptions and allot New Shares under this Offer.

What are the charges?
There are no charges payable by subscribers for the New Shares in addition to the subscription price. All expenses in respect of this Offer are being met by the Company.

As detailed on page 7, the Offer is partially underwritten by the Underwriter pursuant to an underwriting agreement between it and the Company dated 19 December 2007. A 4.0% underwriting fee and a 2.0% management fee totalling A$425,880 (being the equivalent of approximately NZ$487,000) plus GST will be payable by the Company on the underwritten amount to the Underwriter. The Company estimates that its costs in respect of the Offer will be NZ$30,000 plus GST, excluding the underwriting and management fee. In addition the Underwriter will be granted 3,000,000 A$0.25 options over ordinary shares, with a three year term, on completion of the Offer.

A Shareholder in which Mr Trevor Scott, a director of the Company, has an interest has agreed to sub-underwrite the Offer for up to 6,570,000 New Shares, for which it will receive a sub-underwriting commission of 2.5% of the amount ultimately sub-underwritten. This sub-underwriting fee is to be paid by the Underwriter from its fees noted above.

What returns will I get?

**Dividends**
New Shares issued as a result of this Offer will rank equally in all respects, including as to dividends and voting entitlements, with the Existing Shares on issue at the time of allotment. Shareholders will be entitled to receive or benefit from any dividends paid by the Company in respect of New Shares and to any other returns attaching to the New Shares. However, the Company is not intending to pay dividends in the foreseeable future, given that it is intended that the Company will use all available funds for its clinical development and research programmes.

**Sale of New Shares**
Shareholders may benefit from any increase in the market price of their New Shares if they sell them, however the market price of the New Shares may also decline. Factors which may have an influence on the share price of Neuren ordinary shares and, consequently, on returns from the sale of New Shares include:

- prevailing share market conditions;
- general economic conditions;
- interest rate rises or reductions;
- significant changes in the operations or results of Neuren;
- a sale of a significant parcel of Neuren ordinary shares;
- a take-over offer by a third party; and
- the risks described in this Investment Statement under the heading “What are my risks?” below.

**Taxation**
Your return from the New Shares may be affected by taxes or changes to taxation laws. In certain circumstances, gains on the sale of New Shares may be taxable. Generally, where shares are acquired as an investment, New Zealand resident shareholders will not be taxed on gains from a subsequent sale of shares unless the sale is part of a share investment business, the shareholder is in the business of dealing in such investments or acquired the shares with the purpose (or dominant purpose if there is more than one purpose) of sale, or where the sale is part of a profit making undertaking or scheme. These comments, and the descriptions referred to, are of a general nature. They do not constitute legal or financial advice. You should contact your own financial or legal adviser to seek advice concerning the tax consequences of owning or selling New Shares in view of your own particular circumstances.
Neuren Pharmaceuticals Limited
Investment Statement and Prospectus

No guarantee or promise
Neither Neuren, its Directors, nor any person associated with this Offer, guarantees the New Shares or that a dividend will be paid on the New Shares or that the issue price of NZ$0.16 (or A$0.14) per New Share will be recouped. No amount of returns (whether by way of dividend or return on sale or otherwise) on the New Shares is promised or guaranteed by any person. Accordingly, the dates on which, or the frequency with which, returns (if any) on the New Shares will be due and paid are unknown.

What are my risks?
General risk factors
Investments in biopharmaceutical companies can be considered speculative. Risks associated with investment in the Company include risks of a general nature relating to investment in shares and securities generally where the company invested in has a small market capitalisation together with risks particular to investment in the Company, which risks relate to the nature of its activities, being biotechnology research and development.

Investors in the Company will also be subject to normal risks relating to the general levels of economic activity and macro-economic factors beyond the control of the Company including share market conditions which may affect the share market and share prices generally. General risk factors which may have an influence on the share price are described above under the heading “What returns will I get?” and the occurrence of such events, or the specific risk factors detailed below, could result in investors in the Company being unable to recover, or receive any returns on their investment.

Specific risk factors
There are a number of specific risks that may affect Neuren’s operating performance and, consequently, the value of its Shares and returns on the New Shares. Key risks which may affect the value of the New Shares and returns on the New Shares are as follows:

- Reliance on Key Personnel – Neuren currently employs a number of key management and scientific personnel, and in part its future depends on retaining and attracting suitably qualified personnel. Failure to do so could materially adversely affect its business, operating results and financial prospects.

- Contract Risks Generally – Neuren operates through a series of contractual relationships with licensors, sub-licensees, independent contractors, distributors and suppliers. All contracts carry risks associated with the performance by the parties thereto of their obligations as to time and quality of work performed.

- Risk as to Technical Capacity – Neuren intends to carry out development work using appropriately chosen scientific research organisations. As such, it will be subject to the risk that staff in those organisations may have lesser technical capacity than needed to achieve the results sought to be obtained from any development program and the results sought to be obtained may not be obtained or results apparently obtained may be inaccurate as a result of flawed research or development.

- Intellectual Property and Proprietary Rights – Neuren regards the content of certain of its technology as proprietary and relies primarily on a combination of copyright, patent and trade secrecy laws and employee and third party non-disclosure agreements to protect its rights. However, no assurances can be given that employees and/or third parties will not breach non-disclosure agreements or infringe or misappropriate Neuren’s rights. Further, no assurance can be given that others will not challenge the ownership or validity of those proprietary rights by attacking either Neuren or patent holders from whom it has acquired licenses. Litigation may be necessary from time to time to enforce and protect Neuren’s rights. Such litigation can be costly and could have adverse effects on its activities, business, operating results and financial position. It is possible that other parties may assert intellectual property infringement, unfair competition or like claims against Neuren under copyright, trade secret, patent or other laws. While Neuren is not aware of any claims of this nature in relation to any of the intellectual property rights in which it has interests, such claims, if made, may harm, directly and indirectly, its business. If Neuren is forced to defend against claims of intellectual property infringement, whether they are with or without merit or are determined in its favour, it might face costly litigation and diversion of management’s attention. As a result of such disputes, Neuren may have to develop non-infringing technology or enter into royalty or licensing agreements. Such agreements, if necessary, may be unavailable on terms acceptable to Neuren, or at all. If there is a successful claim of intellectual property infringement
Neuren Pharmaceuticals Limited
Investment Statement and Prospectus

or unfair competition against Neuren and it is unable to develop non-infringing technology or license the infringed or similar technology or content on a timely basis, it could harm Neuren’s business, operations and financial condition.

- **Technological Development** – Neuren’s future success will depend in no small part on its ability to develop products that are able to compete in a global marketplace. No assurance can be given that the research and development activities will lead to the development of such products.

- **Competition** – Neuren’s current and potential future competitors might include companies with significantly greater resources than those possessed by the Company. These competitors may develop products or services that are more effective and/or cheaper than those being developed by Neuren, and as a consequence its products or services may become uncompetitive, resulting in adverse effects on revenue, margins and profitability.

- **Product Development** – There are many risks inherent in the development of biotechnology products. They can be subject to many failures during manufacturing and clinical trials or may fail to achieve sufficient robustness and reliability. Neuren cannot guarantee that the development work being undertaken or the milestones sought will result in the development of any products, or even if they do, that those products will be commercially successful.

- ** Sufficiency of Funding** – Neuren has a business plan which will require a high level of expenditure until product revenue streams are established and therefore it expects to continue to incur additional net losses until then. In the future, Neuren will need to raise further financing through other public or private equity financings, collaborations or other arrangements with corporate sources, or other sources of financing to fund operations and achieve milestones. There can be no assurance that such additional financing, if available, can be obtained on terms reasonable to Neuren. In the event Neuren is unable to raise additional capital, future operations will need to be curtailed or discontinued.

- **Regulatory Risks** – Neuren’s operations will require approvals from regulatory authorities which may not be forthcoming or which may not be able to be obtained on acceptable terms. While Neuren has no reason to believe that all requisite approvals will not be forthcoming, investors should be aware that Neuren cannot guarantee that any requisite approvals will be obtained. A failure to obtain any approvals would mean that Neuren’s ability to develop or operate any project may be limited or restricted either in part or absolutely.

- **Risk as to Profitability** – Neuren’s ability to pay dividends will depend on it generating revenue and then deriving sufficient after-tax profits to be able to do so. Neuren is not presently profitable and it may not at any time be so.

- **No Valuation** – No formal or informal valuation has been completed of our intellectual property or assets. We make no representation as to the value of our intellectual property or assets.

- **Risks Related to Liquidity** – Neuren’s Existing Shares quoted on the ASX have limited liquidity. Accordingly, if Neuren successfully applies for quotation on the ASX of the New Shares, there can be no assurance that investors will have sufficient liquidity to sell their Shares through the ASX on a timely basis, at an acceptable price, or at all. As a result of the foregoing, investors may be forced to sell any New Shares acquired in connection with this offering for less than anticipated or even at a loss, or hold their New Shares for longer than anticipated.

- **Generally** – The possibility exists that, for a wide range of reasons, Neuren’s present strategies, plans, policies, intentions and expectations may not be able to be implemented.

**Your liability and consequences of insolvency**

The New Shares allotted under this Offer will be issued fully paid and you will have no liability to Neuren for any further payment in respect of the New Shares.

If the Company becomes insolvent, you would have no obligation to pay any more money to the Company or any other person. Claims on assets of the Company, in the event of the Company being put into liquidation, that rank ahead of the claims of shareholders in the Company are:

- all creditors of the Company, both secured and unsecured; and
- those claims given priority by legislation such as claims for liquidation costs, employees’ wages and taxes.

After all such claims have been paid and made, any remaining assets will be available for distributions to the Company’s Shareholders who will rank equally among themselves. It is reasonably foreseeable that, on termination of your Shares as a
consequence of the Company being put into liquidation, you will have received, in total, less than the amount you have paid for the Shares.

**Can the investment be altered?**

The full terms of this Offer are set out in this Investment Statement and Prospectus. Those terms may be altered by the Company by an amendment to this Investment Statement and Prospectus, details of which must be filed with the Registrar of Companies. However, those terms cannot be altered without your consent once your application for New Shares has been accepted.

The rights attaching to the New Shares are set out under the heading “What sort of investment is this?” and in the section headed “Description of Shares” on pages 19 to 21 of this Investment Statement and Prospectus.

The rights conferred on the Company’s Shareholders are set out in the Companies Act and the Constitution, and also the applicable Listing Rules of the ASX. Shareholders’ rights may be negated, altered or added to by an amendment of the Constitution, which may be made by a special resolution of Shareholders. A special resolution requires the approval of 75% of the votes of shareholders affected by the relevant matter, to be valid.

Neuren may not take any action which would affect the rights of Shareholders without approval by special resolution of those Shareholders whose rights would be affected by the action in question.

Certain major transactions and those that would change the nature of the Company’s business also require the approval of a special resolution.

**How do I cash in my investment?**

Except as otherwise prescribed by law, you have no right to receive back from the Company the amount subscribed for the New Shares offered under this Investment Statement and Prospectus, except in circumstances where the Company is being wound up, or in circumstances where the Company seeks to buy back its own Shares.

A shareholder of New Shares is entitled to sell or transfer their shares to another person by private agreement or on the ASX, subject to compliance with the Constitution and any applicable laws. In the opinion of the Company there is an established market for Neuren’s ordinary shares on the ASX. Following acceptance for quotation by ASX Limited, the New Shares, like the Existing Shares, may be sold or transferred by the holder at any time on the ASX.

Sales through a broker will attract brokerage at the rates charged by that broker. The Company does not charge fees for registering share transfers.

**Who do I contact with enquiries about my investment?**

Enquiries about this Offer may be made to:

The Chief Financial Officer  
Neuren Pharmaceuticals Limited  
Level 1, 103 Carlton Gore Road  
Newmarket, Auckland  
New Zealand  

OR BY MAIL TO: PO Box 9923  
Newmarket, Auckland  
New Zealand  

Telephone: +64 9 529 3940  
Fax: +64 9 529 3941  
Email: enquiries@neurenpharma.com
Enquiries about your present shareholding can be made to:

Neuren Share Registrar
Link Market Services Limited
Level 9, 333 Collins Street
Melbourne, Victoria 3000
Australia
Telephone: +61 3 9615 9800
Fax: +61 3 9615 9900

Is there anyone to whom I can complain if I have problems with the investment?

Any complaints or problems about this Offer can be made to:

The Chairman
Neuren Pharmaceuticals Limited
Level 1, 103 Carlton Gore Road
Newmarket, Auckland
New Zealand
Telephone: +64 9 529 3940
Fax: +64 9 529 3941
Email: enquiries@neurenpharma.com

Complaints about the New Shares cannot be made to any Ombudsman in New Zealand.

What other information can I obtain about this investment?

Other information about Neuren and the New Shares is contained or referred to in the remainder of this Investment Statement and Prospectus (including the unaudited interim financial statements for the six months ended 30 June 2007 set out from page 24), the Constitution, and Neuren’s 2006 Annual Report, which contains the most recent audited financial statements of Neuren for the year ended 31 December 2006. Copies of the Company’s most recent annual and interim reports and financial statements and this Investment Statement and Prospectus may be obtained, free of charge, from the Company’s offices in Auckland (New Zealand) as listed in the Company Directory on page 23, or from the Company’s website www.neurenpharma.com.

The Company is listed on ASX and its Existing Shares are quoted on ASX under the code “NEU”. As such, the Company is a ‘disclosing entity’ for the purposes of the Australian Corporations Act and is subject to regular reporting and disclosure obligations, which require it to disclose to ASX any information of which it is or becomes aware concerning the Company and which a reasonable person would expect to have a material effect on the price or value of securities of the Company. Neuren’s financial reports, corporate presentations and announcements may be viewed on the ASX website www.asx.com.au under the security code “NEU”.

This Investment Statement and Prospectus, the annual financial statements and other documents of, or relating to, the Company (including the Constitution) are also filed on a public register at the Companies Office of the Ministry of Economic Development available (on payment of the relevant fee) at the offices of the Registrar of Companies, Ministry of Economic Development, 135 Albert Street, Auckland and may be viewed online at the website of the Registrar of Companies (www.companies.govt.nz) after they have been scanned and uploaded to that website.

All Shareholders on the relevant record dates will be entitled to receive certain information relating to the ongoing performance of the Company in accordance with the Companies Act, the Financial Reporting Act 1993 and the Listing Rules. The Shareholders will either receive this information automatically or will receive notification of their right to request this
The Company will supply Shareholders or prospective investors with the following documents and information on request:

- a copy of this Investment Statement and Prospectus; and
- a copy of any financial statements of the Company that have been registered under the Financial Reporting Act 1993 (NZ) and that are referred to in this Investment Statement and Prospectus.

Such requests should be made to the Company in writing at the address specified in the Company Directory on page 23, or can be obtained from its offices as listed in the Company Directory on page 23, or from the Company’s website www.neurenpharma.com. The Constitution is also available on request or from the Company’s website.

**MAIN TERMS OF OFFER**

The main terms of the Offer are set out under the headings “What sort of investment is this?” on pages 6 to 7, and “Who is involved in providing it for me?” on pages 7 to 8, of this Investment Statement and Prospectus.

**PROSPECTS**

**Overview**

Neuren is an ASX listed company developing drugs for neurological disorders, metabolism and cancer. The drugs target acute indications of brain injury such as cognitive impairment resulting from cardiac surgery and traumatic brain injury, psychiatric symptoms of stroke, as well as progressive neurological conditions such as Alzheimer’s and Parkinson’s diseases. We are currently enrolling patients in a randomized, double-blind, placebo-controlled Phase 3 clinical trial of one of our lead compounds, Glypromate®, to reduce cognitive impairment in patients following cardiac surgery. This trial will involve approximately 600 completed patients across 24 sites in the U.S., Australia and New Zealand. We expect enrolment to be completed by the end of 2008 and results to be available mid-2009. Approximately 70% of patients who have cardiac surgery with cardiopulmonary bypass experience cognitive decline at discharge and up to 35% of patients exhibit cognitive impairment three months after the procedure. With approximately one million cardiac surgery procedures performed annually in the U.S. and other developed countries, including approximately 800,000 coronary artery bypass graft, or CABG, procedures and 200,000 valve repair or replacements using cardiopulmonary bypass, as many as 350,000 patients per year are left with persistent cognitive impairment.

We have also recently completed a Phase 1b clinical trial of our second product candidate, NNZ-2566, in an intravenous, or IV, formulation for traumatic brain injury, or TBI. In the U.S., approximately 1.4 million people sustain a TBI resulting in more than 50,000 deaths, 1,100,000 patients treated and released from the emergency room and 235,000 patients hospitalised. There presently are no drugs approved for the acute treatment of TBI. The development of NNZ-2566 is being conducted in partnership with the U.S. Army Walter Reed Army Institute of Research.

We are also engaged in preclinical research and development in the treatment of metabolic disorders, such as growth hormone deficiencies, and cancers related to the functions of growth hormone.

On July 31, 2007, we executed a binding term sheet to acquire Hamilton Pharmaceuticals, Inc., a privately-held biopharmaceutical company based in the U.S., whose principal asset is Motiva™, or nefiracetam. The acquisition was completed on 15 October 2007 through the issue of 13,625,443 Neuren Shares. We intend to conduct a Phase 2 clinical trial of

---

1 Based on American Heart Association statistics for valve replacement and bypass surgeries in the US in 2004 together with Neuren’s estimate of an equivalent number of surgeries for the rest of the world (developed countries).
2 Brain Injury Association of America.
Motiva™ as a treatment for post-stroke psychiatric symptoms. Motiva™ has been administered to over 1,700 patients to date in previous Phase 1, 2a and 2b clinical trials in the U.S., Japan and China in which it demonstrated both safety and efficacy. Exclusive, worldwide rights to develop and commercialise Motiva™ were originally licensed by Hamilton from Daiichi Pharmaceutical Co., Ltd., now Daiichi Sankyo Co., Ltd., in 2004.

In conjunction with the acquisition of Hamilton, previous shareholders of Hamilton invested US$3.0 million in a convertible note issued by us that will convert into our ordinary shares on the same terms as, and upon consummation of, a capital raising in which Neuren has received subscriptions for, and issued, new ordinary shares in Neuren for an aggregate of at least US$5 million.

**Product Candidate Pipeline**

Our product candidate pipeline comprises of eight families of compounds across two portfolios, one focused on the central nervous system, or CNS, and the other on growth hormones. Our CNS candidate portfolio is made up of five product families: (i) Glypromate® and NNZ-2566; (ii) Motiva™ (iii) diketopiperazines; (iv) neural regeneration peptides, or NRPs; and (v) macrocyclics. Our growth hormone candidate portfolio is composed of three product families: (i) monoclonal antibodies, or mAbs, against trefoil factors, or TFFs; (ii) human growth hormone variants; and (iii) recently licensed drug discovery and development technology focused on mAbs that target human growth hormone, or hGH, for the potential treatment of cancer.

The following table summarizes our product candidate pipeline. However, there can be no assurance that we will be able to develop, complete development or commercialise any of the following product candidates on a timely basis or at all.

<table>
<thead>
<tr>
<th>Product Candidate</th>
<th>Indication</th>
<th>Stage</th>
<th>Status</th>
<th>Worldwide Commercial Rights</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CNS Portfolio</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glypromate®</td>
<td>Cognitive impairment in cardiac surgery patients</td>
<td>Phase 3</td>
<td>Enrolling</td>
<td>Neuren</td>
</tr>
<tr>
<td>NNZ-2566 (IV)</td>
<td>Traumatic brain injury</td>
<td>Phase 1b</td>
<td>Completed</td>
<td>Neuren</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Phase 2</td>
<td>Developing protocols</td>
<td></td>
</tr>
<tr>
<td>NNZ-2566 (oral)</td>
<td>Traumatic brain injury and stroke recovery</td>
<td>Preclinical</td>
<td>Efficacy testing</td>
<td>Neuren</td>
</tr>
<tr>
<td>Motiva™</td>
<td>Post-stroke depression</td>
<td>Phase 2</td>
<td>Developing protocol</td>
<td>Neuren</td>
</tr>
<tr>
<td>NNZ-2591</td>
<td>Parkinson’s disease and dementia</td>
<td>Preclinical</td>
<td>Efficacy testing</td>
<td>Neuren</td>
</tr>
<tr>
<td>NRPs</td>
<td>Peripheral neuropathy</td>
<td>Preclinical</td>
<td>Lead candidate testing</td>
<td>Neuren / Metabolic Pharmaceuticals</td>
</tr>
<tr>
<td>Macrocyclics</td>
<td>Neurodegenerative diseases</td>
<td>Preclinical</td>
<td>Discovery</td>
<td>Neuren</td>
</tr>
<tr>
<td><strong>Growth Hormone Portfolio</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-TFF mAbs</td>
<td>Oncology</td>
<td>Preclinical</td>
<td>Efficacy testing</td>
<td>Neuren</td>
</tr>
<tr>
<td>hGH variant NNZ-3006</td>
<td>Adult growth hormone deficiency / obesity</td>
<td>Preclinical</td>
<td>Efficacy testing</td>
<td>Neuren</td>
</tr>
<tr>
<td>Anti-hGH mAbs</td>
<td>Oncology</td>
<td>Preclinical</td>
<td>Discovery</td>
<td>Neuren</td>
</tr>
</tbody>
</table>
Milestones and Future Objectives

Since listing on the ASX in January 2005 following the close of our initial public offering, we have accomplished a number of development milestones. These milestones are summarised below, along with some of our key future objectives through 2009. However, there can be no assurance that we will be able to achieve any of the future objectives described below on a timely basis or at all.

2005

- Formed collaboration with Metabolic Pharmaceuticals Limited for the development of NRPs
- Executed Cooperative Research and Development Agreement with the U.S. Army for NNZ-2566 in TBI
- Results from animal models presented by the U.S. Army at the Advanced Technology Applications for Combat Casualty Care conference confirming that NNZ-2566 significantly reduced functional deficits from severe TBI
- Initiated enrolment in our Phase 2a trial of Glypromate® in patients who underwent CABG surgery
- Received two U.S. patents for Glypromate® in Parkinson’s disease

2006

- Announced preclinical results for oral administration of NNZ-2566 indicating significant neuroprotection at various doses
- Initiated a Phase 1a trial of IV administration of NNZ-2566 for TBI in healthy volunteers
- Received U.S. composition of matter and method of use patent for NNZ-2566 in all formulations
- Results from animal models in stroke presented by the U.S. Army at the International Neurotrauma Symposium confirming that NNZ-2566 inhibits non-convulsive seizures
- Completed and announced favourable safety and pharmacokinetic data from our Phase 2a trial of Glypromate® in patients who underwent CABG surgery
- Announced preclinical results for NNZ-3006, a novel, naturally occurring variant of human growth hormone, demonstrating its ability to reduce fat deposits in two animal models without unwanted side effects
- Announced preclinical results for NNZ-2591, an orally administered diketopiperazine, demonstrating improved performance in a preclinical animal model of learning and memory
- Announced preclinical results for anti-TFF monoclonal antibodies in vitro and for anti-TFF polyclonal antibodies in a xenograft model of breast cancer
- Filed an Investigational New Drug application, or IND, for Glypromate® with the FDA

2007

- Completed and announced favourable safety and tolerability data from the Phase 1a trial of IV administration of NNZ-2566 in healthy volunteers
- Initiated enrolment in our Phase 3 trial of Glypromate® to reduce cognitive impairment in patients following cardiac surgery with cardiopulmonary bypass
- Executed a license agreement with the University of Auckland for a discovery-stage anti-cancer program based on development of antibodies against human growth hormone, or hGH, in hGH-producing cancers
- Initiated enrolment in our Phase 1b trial of NNZ-2566 in healthy volunteers
- Acquired Hamilton Pharmaceuticals, incorporating Motiva™
- Completed and announced favourable safety, tolerability and pharmacokinetic data from our Phase 1b trial of NNZ-2566 in healthy volunteers

Future Objectives³

- Initiate a Phase 2 trial of the IV formulation of NNZ-2566 in mild-to-moderate TBI in mid-2008

³ The successful completion of this Offer, together with further capital raising, joint venture and licensing opportunities are necessary to fund all of the future objectives noted.
• Initiate a Phase 2a trial of the IV formulation of NNZ-2566 in severe TBI in mid-2008
• Data Safety Monitoring Committee to perform interim, unblinded safety analysis of our Phase 3 trial of Glypromate® in mid-2008
• Initiate a Phase 2b trial of Motiva™ in post-stroke psychiatric symptoms in mid-2008
• Complete enrolment in our Phase 3 trial of Glypromate® in late 2008
• Complete and announce results of our Phase 3 trial of Glypromate® in mid-2009
• Complete and announce results of our Phase 2 trial of the IV formulation of NNZ-2566 in mild-to-moderate TBI in mid-2009
• Complete and announce results of our Phase 2a trial of the IV formulation of NNZ-2566 in severe TBI in mid-2009
• Complete and announce results of our Phase 2 trial of Motiva™ in post-stroke psychiatric symptoms in mid-2009

Purpose of the Offer and Use of Proceeds
Neuren has a number of initiatives underway both locally (Australia and New Zealand) and internationally to raise further capital for the Company through the issue of securities to new investors. The Company is also actively pursuing a number of licensing and/or joint venture initiatives to assist in the funding required to take its pipeline of lead compounds through the next stage of clinical trials. The Directors have decided that until such funding is available, the primary focus of the Company should be the completion of the current Phase 3 Glypromate® trial and that this should be funded through this Offer. If the Offer proceeds as contemplated and is fully subscribed, the total capital raise of A$10.1 million (gross) will support completion of the first Glypromate® Phase 3 trial as well as associated overhead and corporate operating expenses. The underwritten amount of A$7.1 million which is the minimum that will be raised under this Offer will trigger conversion of the outstanding convertible notes held by the former Hamilton Pharmaceuticals shareholders, will support Glypromate® clinical trial costs and overhead through 2008 and will allow other capital raising, joint venture and licensing opportunities currently underway to be pursued.

As this Offer is partially underwritten, the Directors have not established a minimum amount which must be raised before the Directors will accept subscriptions and allot New Shares under this Offer.

Special Trade Factors and Risks
The general risks and special trade factors and risks which investors should consider before they make a decision whether or not to invest in the Company are set out under the heading “What are my risks?” on pages 11 to 13.

ISSUE EXPENSES

The total expenses of the issue payable by the Company, including all legal costs, accounting fees, printing costs, share registry and other costs, are estimated to be NZ$30,000 plus GST, excluding the underwriting and management fee which will be A$425,880 (approximately NZ$487,000) plus GST, and the 3,000,000 A$0.25 options over ordinary shares, with a three year term, to be granted to the Underwriter on completion of the Offer.

A Shareholder in which Mr Trevor Scott, a director of the Company, has an interest has agreed to sub-underwrite the Offer for up to 6,570,000 New Shares, for which it will receive a sub-underwriting commission of 2.5% of the amount ultimately sub-underwritten. This sub-underwriting fee is to be paid by the Underwriter from its fees noted above.

No brokerage is payable by any Shareholder subscribing for New Shares comprising their Entitlement. The Company may at its discretion pay a commission on a Shortfall Application received, in particular in respect of applications bearing a broker stamp at the rate of between 2.5% and 5.0%, provided the Shortfall Application is accepted by the Directors and New Shares are subsequently allotted. The payment of any commission will be made 14 days after acceptance by the Company of a Shortfall Application.
OTHER TERMS OF OFFER AND SECURITIES

All terms of the New Shares being offered are set out in this Investment Statement and Prospectus, except for those implied by law or set out in a document that:

(a) has been registered with a public official;
(b) is available for public inspection; and
(c) is referred to in this Investment Statement and Prospectus.

The date of the most recent audited financial statements of the Company is 31 December 2006 contained in the Annual Report 2006. Unaudited interim financial statements for the six months ended 30 June 2007 are contained in this Investment Statement and Prospectus from page 24. Both the Annual Report 2006 and Interim Report 2007 have previously been sent to Shareholders.

A copy of the Company’s Annual Report 2006 and Interim Report 2007 can be obtained free of charge on request to the Company at PO Box 9923, Newmarket, Auckland (telephone: (09) 529 3940). They may also be obtained free of charge from the Company’s website www.neurenpharma.com or the ASX website www.asx.com.au under the security code “NEU”.

DESCRIPTION OF SHARES

The Shares are fully paid ordinary shares and are all of the same class and rank equally in every respect. Set out below is a summary of some of the principal rights of Shareholders pursuant to the Constitution. It does not purport to constitute an exhaustive or definitive statement of the rights and liabilities of the Shareholders. Investors are accordingly encouraged to inspect the Constitution.

The rights and liabilities attaching to the Shares are also regulated by the New Zealand Companies Act, the general law and the Listing Rules of the ASX.

Meetings of Shareholders

Each Shareholder is entitled to receive a notice of and attend and vote at general meetings of the Company and to receive all notices, reports and financial statements required to be sent to Shareholders under the Constitution, the Companies Act, the Listing Rules or other requirements.

The Company may serve a notice on the Shareholder either personally, by sending it by post addressed to the Shareholder’s registered address or to the Shareholder’s email address.

Voting Rights

At a general meeting, subject to any special privileges or restrictions as to voting for the time being attached to any special class of shares, on a show of hands every Shareholder present in person or by proxy has one vote. On a poll, each Shareholder present in person or by proxy will have one vote for every Share which that Shareholder holds or represents. No Shareholder will be entitled, in respect of Shares held by that Shareholder, to exercise voting rights or to form part of any quorum by virtue of his or her holding such Shares if any call or other sum presently payable by that member to the Company in respect of such Shares remains unpaid.

Subject to the Companies Act, the general law and the Listing Rules, in the case of equality of votes, whether on a show of hands by voice or on a poll, the Chairman of that Shareholders’ meeting is not entitled to a second or casting vote.
Dividend Rights
The Directors, in accordance with the Companies Act, may declare dividends.

Unless and to the extent that the rights attached to any shares or the terms of issue thereof otherwise provide, all dividends will (as regards any Shares not fully paid throughout the period in respect of which the dividend is paid) be apportioned and paid pro rata according to the amount paid on the Shares during any portion or portions of the period in respect of which the dividend is paid. For this purpose, no amount paid on a Share in advance of calls will be treated as paid on the share.

Transfer of Shares
Shares may be transferred electronically (by an electronic transfer system approved by any statute of New Zealand) or by instrument in a form as approved by the Directors and any stock exchange upon which the Company may be listed.

There will be no restriction on the transfer of Shares except where:
- required by law, the listing rules of any stock exchange upon which the Shares may be listed; or
- where the Board in its discretion granted by the Constitution refuses to transfer the Shares.

Issue of Further Shares
Subject to the Companies Act, the Listing Rules and any special rights previously conferred on the holders of any existing shares or class of shares, the Directors may issue shares at any time without the prior approval of the Company in a general meeting, to any persons on such terms and conditions and for such consideration and at such time and on such payment terms as the Directors may think fit.

Any shares may be issued in such denomination or with such preferential, deferred, qualified or special rights, privileges, conditions or restrictions or limitations including as to distributions, voting rights and ranking as the Directors may think fit.

Variation of Rights
The issue of shares ranking equally with or in priority to any existing shares will not affect the rights of the existing shares unless specifically provided for in the terms of issue of those existing shares.

Winding Up
If the Company is wound up (whether the liquidation is voluntary, under supervision, or by the court) the liquidator may, with the authority of a special resolution or any other sanction required by the Companies Act, divide among the members in kind the whole or any part of the assets of the Company and whether or not the assets will consist of property of the same or different kinds, and may for such purpose set such value as the liquidator deems fair upon any of the property to be divided as aforesaid and may determine how such division will be carried out as between the members or different classes of members.

The liquidator may, with the approval of the Company by special resolution, vest the whole or any part of the assets in trustees upon such trusts for the benefit of members as the liquidator with the approval of the Company by special resolution will think fit, and the Company dissolved, but so that no contributory will be compelled to accept any shares or other property in respect of which there is a liability.
Share Buy Backs
The Company may buy Shares in itself on the terms and at the times determined by the Board, to extent and in the manner permitted by the listing rules of any stock exchange upon which the shares of the Company may be listed and the Companies Act.

Compliance with ASX Listing Rules
The Constitution was amended on 4 October 2004 to incorporate Appendix 15A of the Listing Rules of the ASX. Accordingly, the following applies:

- Notwithstanding anything contained in the Constitution, if the Listing Rules prohibit an act being done, the act shall not be done.
- Nothing contained in the Constitution prevents an act being done that the Listing Rules require to be done.
- If the Listing Rules require an act to be done or not to be done, authority is given for that act to be done or not to be done (as the case may be).
- If the Listing Rules require the Constitution to contain a provision and it does not contain such a provision, the Constitution is deemed to contain that provision.
- If the Listing Rules require the Constitution not to contain a provision and it contains such a provision the Constitution is deemed not to contain that provision.
- If any provision of the Constitution is or becomes inconsistent with the Listing Rules, the Constitution is deemed not to contain that provision to the extent of the inconsistency.

Alteration of Constitution
The Constitution can only be amended by a special resolution passed by at least 75% of the votes cast by Shareholders present and voting at the general meeting. At least 10 business days’ written notice specifying the intention to propose the resolution as a special resolution must be given.

Number of Directors
The number of Directors, other than alternate directors, will not be less than 3 or more than 9 or such other number as is fixed by an ordinary resolution of the Company. At least 2 Directors of the Company must be ordinarily resident in New Zealand.

Appointment and Removal of Directors
Subject to the Constitution, the Board or the Company by ordinary resolution may appoint any person as a Director either to fill a casual vacancy or as an additional Director.

The Listing Rules require that the Company hold an election of Directors by ordinary resolution each year. The Directors, other than a managing director, must not hold office (without re-election) past the third annual meeting of Shareholders following the Director’s appointment or 3 years, whichever is longer. However, a Director appointed to fill a casual vacancy or as an addition to the Board must not hold office (without re-election) past the next annual meeting of Shareholders.

The Company may by ordinary resolution, subject to the Constitution, from time to time remove any Director before the expiration of his or her period of office and appoint another person in their place.
The Directors of Neuren, after due enquiry by them in relation to the period between 30 June 2007 and the date of registration of this Investment Statement and Prospectus, are of the opinion that the only circumstance that has arisen that materially adversely affects Neuren’s trading or profitability or the value of its assets or its ability to pay its liabilities due within the next twelve months, is that Neuren has been unable to secure a significant equity injection from one or more institutional investors during that period. The underwritten amount of this offer (A$7.1 million) is the amount the Directors reasonably believe the Company requires to provide for the Company’s operating expenses until further financing can be arranged as a result of initiatives currently underway. There can be no assurance that additional financing beyond this Offer can be obtained or, if obtainable, that the terms will be reasonable. If the Company is unable to raise the full amount of this offer and/or such further funding, future operations will need to be curtailed or discontinued.

This Investment Statement and Prospectus has been signed by each Director of the Company or by their agent authorised in writing.

Chairman
Dr Robin Congreve

Director
Mr Tom Amos

Director
Dr Graeme Howie

Director
Mr Trevor Scott

Director
Dr Douglas Wilson
COMPANY DIRECTORY

Directors
Dr Robin Congreve
Mr Tom Amos
Dr Graeme Howie
Mr Trevor Scott
Dr Douglas Wilson

Broker and Underwriter to the Offer
Taylor Collison Limited
Level 10, 167 Macquarie Street
Sydney NSW 2000
Tel: +61 2 9232 1688

Company Secretary
Mr Robert Waring

Auditor
PricewaterhouseCoopers
188 Quay Street
Private Bag 92162
Auckland, New Zealand

Registered and Corporate Head Office
Level 1
103 Carlton Gore Road
Newmarket, Auckland
New Zealand
Tel: +64 9 529 3940
Fax: +64 9 529 3941

Australian Registered Office
Level 13
122 Arthur Street
North Sydney NSW 2060
Tel: +61 2 9956 8500

Share Registrar
Link Market Services Limited
Level 9, 333 Collins Street
Melbourne, Victoria 3000
Australia
Tel: +61 3 9615 9800
Fax: +61 3 9615 9900
DEFINITIONS AND INTERPRETATIONS

$ or NZ$ refers to New Zealand dollars

A$ refers to Australian dollars

Application Form the combined Entitlement & Acceptance and Shortfall Application Form that accompanies the Investment Statement and Prospectus for holders of Existing Shares as at the Record Date whose registered address is in New Zealand

Application Monies the total monies payable by an applicant at the time of subscribing for a specified number of the New Shares

ASX ASX Limited or the Australian Securities Exchange that it operates (as the context requires)

Board the board of Directors of the Company

Close or Closing Date the date so described in the table on page 2 of this Investment Statement and Prospectus

Companies Act the New Zealand Companies Act 1993

Company or Neuren Neuren Pharmaceuticals Limited (New Zealand Registered Company Number 1181152; Australian Registered Body Number 111 496 130), including its subsidiaries

Constitution the constitution of the Company as amended from time to time

Corporations Act the Australian Corporations Act 2001 (Cth)

Director a director of the Company

Entitlement the number of New Shares to which a Shareholder with a registered address in New Zealand or Australia at 5 p.m. (New Zealand time) on the Record Date is entitled to apply for under this Offer and as set out in the Application Form

Existing Share a fully paid ordinary share in the Company on issue at 9 p.m. on the Record Date

Investment Statement and Prospectus this Investment Statement and Prospectus dated 19 December 2007

Listing Rules the listing rules of the ASX as amended from time to time and for so long as the Company is admitted to the official list of the ASX

New Shares up to 72,369,626 new ordinary shares in the Company offered to New Zealand and Australian resident shareholders pursuant to the Offer

Offer this offer of New Shares made by the Company as set out in this Investment Statement and Prospectus

Record Date 9 p.m. (New Zealand time) on 2 January 2008

Share one ordinary fully paid share in the Company, be it an Existing Share or a New Share

Shareholder a holder of Existing Shares in the Company

Shortfall the total New Shares from Entitlements not accepted by Shareholders under this Offer

Shortfall Application an application for an allocation of New Shares, in excess of the Entitlement, from the Shortfall

Underwriter Taylor Collison Limited (ACN 008 172 450)

INTERIM FINANCIAL STATEMENTS

The interim financial statements of Neuren for the six months ended 30 June 2007 are set out from the next page.
Unaudited Interim Financial Statements
for the six months ended 30 June 2007

Contents

Interim Income Statement 1
Interim Balance Sheet 2
Interim Statement of Changes in Equity 3
Interim Cash Flow Statement 4
Notes to the Interim Financial Statements 5 - 15
## Interim Income Statement (Unaudited)
for the six months ended 30 June 2007

<table>
<thead>
<tr>
<th>Company and Group</th>
<th>Six months June 2007 NZ$’000</th>
<th>Six months June 2006 NZ$’000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue - interest income</td>
<td>207</td>
<td>285</td>
</tr>
<tr>
<td>- contract research revenue</td>
<td>-</td>
<td>136</td>
</tr>
<tr>
<td>Other income - grants</td>
<td>571</td>
<td>671</td>
</tr>
<tr>
<td>Total revenue and other income</td>
<td>778</td>
<td>1,092</td>
</tr>
<tr>
<td>Depreciation and amortisation expense</td>
<td>(469)</td>
<td>(441)</td>
</tr>
<tr>
<td>Research and development costs</td>
<td>(6,630)</td>
<td>(4,113)</td>
</tr>
<tr>
<td>Patent costs</td>
<td>(144)</td>
<td>(417)</td>
</tr>
<tr>
<td>Share option compensation expense</td>
<td>(248)</td>
<td>(35)</td>
</tr>
<tr>
<td>Foreign exchange gain (loss)</td>
<td>(204)</td>
<td>1,216</td>
</tr>
<tr>
<td>Corporate and administrative costs</td>
<td>(1,311)</td>
<td>(1,238)</td>
</tr>
<tr>
<td><strong>Loss before income tax</strong></td>
<td>(8,228)</td>
<td>(3,936)</td>
</tr>
<tr>
<td>Income tax expense</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Loss after income tax</strong></td>
<td>$ (8,228)</td>
<td>$ (3,936)</td>
</tr>
<tr>
<td>Basic and diluted loss per share</td>
<td>$ (0.06)</td>
<td>$ (0.04)</td>
</tr>
</tbody>
</table>

The accompanying notes form part of this financial report.
### Interim Balance Sheet (Unaudited)

as at 30 June 2007

<table>
<thead>
<tr>
<th>Company and Group</th>
<th>Notes</th>
<th>As at June 2007 NZ$’000</th>
<th>As at Dec 2006 NZ$’000</th>
<th>As at June 2006 NZ$’000</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Current Assets:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>7</td>
<td>4,506</td>
<td>10,609</td>
<td>9,068</td>
</tr>
<tr>
<td>Trade and other receivables</td>
<td>8</td>
<td>349</td>
<td>994</td>
<td>1,062</td>
</tr>
<tr>
<td>Other current assets</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td></td>
<td>4,861</td>
<td>11,609</td>
<td>10,136</td>
</tr>
<tr>
<td><strong>Non-current assets:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Property, plant and equipment</td>
<td>9</td>
<td>318</td>
<td>303</td>
<td>71</td>
</tr>
<tr>
<td>Intangible assets</td>
<td>10</td>
<td>9,579</td>
<td>9,986</td>
<td>10,393</td>
</tr>
<tr>
<td><strong>Total non-current assets</strong></td>
<td></td>
<td>9,897</td>
<td>10,289</td>
<td>10,464</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td></td>
<td>$ 14,758</td>
<td>$ 21,898</td>
<td>$ 20,600</td>
</tr>
</tbody>
</table>

| **LIABILITIES AND SHAREHOLDERS’ EQUITY**   |       |                         |                        |                        |
| **Current liabilities:**                   |       |                         |                        |                        |
| Trade and other payables                   | 11    | 4,538                   | 3,698                  | 3,215                  |
| Lease incentive – short term               |       | 15                      | 15                     | -                      |
| **Total current liabilities**              |       | 4,553                   | 3,713                  | 3,215                  |
| **Non-current liabilities:**               |       |                         |                        |                        |
| Lease incentive – long term                |       | 68                      | 75                     | -                      |
| **Total liabilities**                      |       | 4,621                   | 3,788                  | 3,215                  |

| **SHAREHOLDERS’ EQUITY**                   |       |                         |                        |                        |
| Share capital                              | 12    | 49,950                  | 49,943                 | 41,875                 |
| Other reserves                             |       | 834                     | 586                    | 519                    |
| Accumulated deficit                        |       | (40,647)                | (32,419)               | (25,009)               |
| **Total shareholders’ equity**             |       | 10,137                  | 18,110                 | 17,385                 |

| **TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY** |       | $ 14,758                | $ 21,898               | $ 20,600               |

The accompanying notes form part of this financial report.
# Interim Statement of Changes in Equity (Unaudited)
## for the six months ended 30 June 2007

<table>
<thead>
<tr>
<th>Company and Group</th>
<th>Shares 000’s</th>
<th>NZ$’000</th>
<th>NZ$’000</th>
<th>NZ$’000</th>
<th>NZ$’000</th>
<th>NZ$’000</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Paid-in Capital</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shareholders’ equity as at 1 January 2006</td>
<td>112,000</td>
<td>$41,877</td>
<td>$484</td>
<td>$(21,073)</td>
<td>$21,288</td>
<td></td>
</tr>
<tr>
<td>Share issue costs expensed</td>
<td></td>
<td></td>
<td>(2)</td>
<td>(2)</td>
<td>(2)</td>
<td>(2)</td>
</tr>
<tr>
<td>Share option grants for services</td>
<td></td>
<td></td>
<td>35</td>
<td>35</td>
<td>35</td>
<td>35</td>
</tr>
<tr>
<td>Loss for the period</td>
<td></td>
<td></td>
<td>(3,936)</td>
<td>(3,936)</td>
<td>(3,936)</td>
<td>(3,936)</td>
</tr>
<tr>
<td><strong>Total recognised income and expenses</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(3,936)</td>
<td>(3,936)</td>
</tr>
<tr>
<td>Shareholders’ equity as at 30 June 2006</td>
<td>112,000</td>
<td>$41,875</td>
<td>$519</td>
<td>$(25,009)</td>
<td>$17,385</td>
<td></td>
</tr>
<tr>
<td>Shares issued in private placement</td>
<td>15,000</td>
<td>6,705</td>
<td>6,705</td>
<td>6,705</td>
<td>6,705</td>
<td>6,705</td>
</tr>
<tr>
<td>Shares issued in Share Purchase Plan</td>
<td>4,094</td>
<td>1,871</td>
<td>1,871</td>
<td>1,871</td>
<td>1,871</td>
<td>1,871</td>
</tr>
<tr>
<td>Share issue costs expensed</td>
<td></td>
<td>(508)</td>
<td>(508)</td>
<td>(508)</td>
<td>(508)</td>
<td>(508)</td>
</tr>
<tr>
<td>Share option grants for services</td>
<td></td>
<td>67</td>
<td>67</td>
<td>67</td>
<td>67</td>
<td>67</td>
</tr>
<tr>
<td>Loss for the period</td>
<td></td>
<td>(7,410)</td>
<td>(7,410)</td>
<td>(7,410)</td>
<td>(7,410)</td>
<td>(7,410)</td>
</tr>
<tr>
<td><strong>Total recognised income and expenses</strong></td>
<td></td>
<td></td>
<td></td>
<td>$ (11,346)</td>
<td>(11,346)</td>
<td>(11,346)</td>
</tr>
<tr>
<td>Shareholders’ equity as at 31 December 2006</td>
<td>131,094</td>
<td>$49,943</td>
<td>$586</td>
<td>$(32,419)</td>
<td>$18,110</td>
<td></td>
</tr>
<tr>
<td>Shares issued on option exercise</td>
<td>20</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Share issue costs expensed</td>
<td></td>
<td>(1)</td>
<td>(1)</td>
<td>(1)</td>
<td>(1)</td>
<td>(1)</td>
</tr>
<tr>
<td>Share option grants for services</td>
<td></td>
<td>248</td>
<td>248</td>
<td>248</td>
<td>248</td>
<td>248</td>
</tr>
<tr>
<td>Loss for the period</td>
<td></td>
<td>(8,228)</td>
<td>(8,228)</td>
<td>(8,228)</td>
<td>(8,228)</td>
<td>(8,228)</td>
</tr>
<tr>
<td><strong>Total recognised income and expenses</strong></td>
<td></td>
<td></td>
<td></td>
<td>$ (8,228)</td>
<td>(8,228)</td>
<td>(8,228)</td>
</tr>
<tr>
<td>Shareholders’ equity as at 30 June 2007</td>
<td>131,114</td>
<td>$49,950</td>
<td>$834</td>
<td>$(40,647)</td>
<td>$10,137</td>
<td></td>
</tr>
</tbody>
</table>

The accompanying notes form part of this financial report.
Notes to the Interim Financial Statements (Unaudited)
for the six months ended 30 June 2007

<table>
<thead>
<tr>
<th>Company and Group</th>
<th>Six months June 2007 NZ$’000</th>
<th>Six months June 2006 NZ$’000</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from operating activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Receipts from customers</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Receipts from grants</td>
<td>794</td>
<td>883</td>
</tr>
<tr>
<td>Interest received</td>
<td>207</td>
<td>284</td>
</tr>
<tr>
<td>GST refunded</td>
<td>230</td>
<td>117</td>
</tr>
<tr>
<td>Payments to employees</td>
<td>(1,410)</td>
<td>(1,115)</td>
</tr>
<tr>
<td>Income taxes (paid) refunded</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Payments to other suppliers</td>
<td>(5,631)</td>
<td>(4,742)</td>
</tr>
<tr>
<td><strong>Net cash used in operating activities</strong></td>
<td>(5,810)</td>
<td>(4,573)</td>
</tr>
<tr>
<td><strong>Cash flows from investing activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchase of plant and equipment</td>
<td>(103)</td>
<td>(16)</td>
</tr>
<tr>
<td>Purchase of software</td>
<td>(16)</td>
<td>(8)</td>
</tr>
<tr>
<td><strong>Net cash used in investing activities</strong></td>
<td>(119)</td>
<td>(24)</td>
</tr>
<tr>
<td><strong>Cash flows from financing activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proceeds from the issue of shares</td>
<td>8</td>
<td>-</td>
</tr>
<tr>
<td>Payments for share issue expenses</td>
<td>(21)</td>
<td>(49)</td>
</tr>
<tr>
<td><strong>Net cash from (used in) financing activities</strong></td>
<td>(13)</td>
<td>(49)</td>
</tr>
<tr>
<td><strong>Net increase (decrease) in cash held</strong></td>
<td>(5,942)</td>
<td>(4,646)</td>
</tr>
<tr>
<td>Effect of exchange rate changes on cash balances</td>
<td>(161)</td>
<td>1,215</td>
</tr>
<tr>
<td>Cash at the beginning of the period</td>
<td>10,609</td>
<td>12,499</td>
</tr>
<tr>
<td><strong>Cash at the end of the period</strong></td>
<td>$ 4,506</td>
<td>$ 9,068</td>
</tr>
<tr>
<td><strong>Reconciliation with loss after income tax:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loss after income tax</td>
<td>$ (8,228)</td>
<td>$ (3,936)</td>
</tr>
<tr>
<td>Non-cash items requiring adjustment:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation of property, plant and equipment</td>
<td>45</td>
<td>25</td>
</tr>
<tr>
<td>Amortisation of intangible assets</td>
<td>424</td>
<td>416</td>
</tr>
<tr>
<td>Share option compensation expense</td>
<td>248</td>
<td>35</td>
</tr>
<tr>
<td>Lease incentive amortisation</td>
<td>(7)</td>
<td>-</td>
</tr>
<tr>
<td>Foreign exchange loss (gain)</td>
<td>204</td>
<td>(1,216)</td>
</tr>
<tr>
<td><strong>Movements in working capital:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trade and other receivables</td>
<td>370</td>
<td>159</td>
</tr>
<tr>
<td>Trade and other payables</td>
<td>1,134</td>
<td>(56)</td>
</tr>
<tr>
<td><strong>Net cash used in operating activities</strong></td>
<td>$ (5,810)</td>
<td>$ (4,573)</td>
</tr>
</tbody>
</table>

The accompanying notes form part of this financial report.
Notes to the Interim Financial Statements (Unaudited)
for the six months ended 30 June 2007

1. Nature of business

Neuren Pharmaceuticals Limited (Neuren or the Company) is a publicly listed biopharmaceutical company focusing on the development of therapeutics for conditions associated with brain injury and neurodegeneration, including acute indications such as cognitive impairment resulting from cardiac surgery and traumatic brain injury, as well as chronic conditions such as Alzheimer’s and Parkinson’s diseases. In addition, the Company is engaged in research and development in metabolic disorders such as obesity, growth disturbances and cancers related to the functions of growth hormone. Neuren operates predominantly from New Zealand.

The Company is a limited liability company incorporated and domiciled in New Zealand. The address of its registered office in New Zealand is level 1, 103 Carlton Gore Road, Auckland, and in Australia Level 13, 122 Arthur Street, North Sydney. Neuren has its primary listing on the Australian Securities Exchange (ASX code: NEU).

These consolidated interim financial statements have been approved for issue by the Board of Directors on 29 August 2007.

Inherent Uncertainties

• There are inherent uncertainties associated with assessing the carrying value of the acquired intellectual property. The ultimate realisation of the carrying values of intellectual property totalling $9,555,000 (after amortisation) is dependent on the Company successfully developing its products, on licensing the products, or divesting the intellectual property so that it generates future economic benefits to the Company.

• The Company’s research and development activities involve inherent risks. These risks include, among others: dependence on, and the Company’s ability to retain key personnel; the Company’s ability to protect its intellectual property and prevent other companies from using the technology; the Company’s business is based on novel and unproven technology; the Company’s ability to sufficiently complete the clinical trials process; and technological developments by the Company’s competitors may render its products obsolete.

• The Company has a business plan which will require a high level of expenditure until product revenue streams are established and therefore expects to continue to incur additional net losses until then. In the future, the Company will need to raise further financing through other public or private equity financings, collaborations or other arrangements with corporate sources, or other sources of financing to fund operations. There can be no assurance that such additional financing, if available, can be obtained on terms reasonable to the Company. In the event the Company is unable to raise additional capital, future operations will need to be curtailed or discontinued.

2. Summary of significant accounting policies

These general-purpose interim financial statements are for the six months ended 30 June 2007 and have been prepared in accordance with generally accepted accounting practice in New Zealand.

The accounting policies that materially affect the measurement of the Income Statement, Balance Sheet and the Cash Flow Statement have been applied on a basis consistent with those used in the audited financial statements for the year ended 31 December 2006 and the unaudited financial statements for the six months ended 30 June 2006.

(a) Basis of preparation

Entities Reporting

These financial statements are for the Company and the Group (comprising the Company and its subsidiaries) which are designated as profit-oriented entities for financial reporting purposes. At 30 June 2006 and 2007 the subsidiary companies had no material operations.

Statutory Base

Neuren is registered under the New Zealand Companies Act 1993 and is an issuer in terms of the New Zealand Securities Act 1978. Neuren is also registered as a foreign company under the Australian Corporations Act 2001.

These financial statements have been prepared in accordance with the requirements of the Financial Reporting Act 1993 and the Companies Act 1993.

Historical cost convention

These financial statements have been prepared under the historical cost convention as modified by certain policies below.

Critical accounting estimates

The preparation of financial statements requires the use of certain critical accounting estimates. It also requires the Company to exercise its judgement in the process of applying the Company’s accounting policies. Actual results may differ from those estimates.
There have been no significant changes in accounting policies during the current period. The accounting policies set out below have been applied on a basis consistent with the comparative interim period and the annual financial statements.

(b) Revenue recognition

Grants
Grants received are recognised in the income statement when the requirements under the grant agreement have been met. Any grants for which the requirements under the grant agreement have not been completed are carried as liabilities until all the conditions have been fulfilled.

Contract research
Where science projects are recognised on an individual project basis and span more than one year, the percentage completion method is used to determine the appropriate amount of revenue to recognise in a given year over the life of the project. Contract revenue is recognised when earned and non-refundable and when there are no future obligations pursuant to the revenue, in accordance with the contract terms. The full amount of an anticipated loss, including that relating to future work on the contract, is recognised as soon as it is foreseen.

Interest income
Interest income is recognised on a time-proportion basis using the effective interest method.

(c) Research and development
Research costs include direct and directly attributable overhead expenses for drug discovery, research and pre-clinical and clinical trials. Research costs are expensed as incurred.

When a project reaches the stage where it is reasonably certain that future expenditure can be recovered through the process or products produced, development expenditure is recognised as a development asset when:

- a product or process is clearly defined and the costs attributable to the product or process can be identified separately and measured reliably;
- the technical feasibility of the product or process can be demonstrated;
- the existence of a market for the product or process can be demonstrated and the Company intends to produce and market the product or process;
- adequate resources exist, or their availability can be reasonably demonstrated to complete the project and market the product or process.

In such cases the asset is amortised from the commencement of commercial production of the product to which it relates on a straight-line basis over the years of expected benefit. Research and development costs are otherwise expensed as incurred.

(d) Translation of foreign currency
The financial statements are expressed in New Zealand dollars, the functional currency of the Company. Transactions denominated in a foreign currency are converted to New Zealand dollars at the exchange rates in effect at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies arising from operations are translated into New Zealand dollars using closing exchange rates in effect at period-end. Gains and losses due to exchange rate fluctuations on these items are included in the income statement.

(e) Income tax
The income tax expense for the period is the tax payable on the period’s taxable income or loss using tax rates enacted at the balance sheet date and adjusted by changes in deferred tax assets and liabilities attributable to temporary differences between the tax bases of assets and liabilities and their carrying amounts in the financial statements, and to unused tax losses.

Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to apply when the assets are recovered or liabilities are settled, based on those tax rates which are enacted or substantively enacted at the balance sheet date. The relevant tax rates are applied to the cumulative amounts of deductible and taxable temporary differences to measure the deferred tax asset or liability. An exception is made for certain temporary differences arising from the initial recognition of an asset or a liability. No deferred tax asset or liability is recognised in relation to these temporary differences if they arose in a transaction, other than a business combination, that at the time of the transaction did not affect either accounting profit or taxable profit or loss.

Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

Current and deferred tax balances attributable to amounts recognised directly in equity are also recognised directly in equity.

(f) Leases
Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases (net of any incentives received from the lessor) are charged to the income statement on a straight-line basis over the period of the lease.
Notes to the Interim Financial Statements (Unaudited)
for the six months ended 30 June 2007

(g) Impairment of non-financial assets
Assets that have an indefinite useful life are not subject to amortisation and are tested annually for
impairment. Assets that are subject to amortisation are reviewed whenever events or changes in
circumstances indicate that the carrying amount of the assets may not be recoverable. The carrying amount
of a long-lived asset is considered impaired when the recoverable amount from such asset is less than its
carrying value. In that event, a loss is recognised in the income statement based on the amount by which the
carrying amount exceeds the fair market value of the long-lived asset. Fair market value is determined using
the anticipated cash flows discounted at a rate commensurate with the risk involved.

(h) Goods and services tax (GST)
The financial statements have been prepared so that all components are presented exclusive of GST. All
items in the balance sheet are presented net of GST, with the exception of receivables and payables, which
include GST invoiced.

(i) Intellectual property
Costs in relation to protection and maintenance of intellectual property are expensed as incurred unless the
project has yet to be recognised as commenced, in which case the expense is deferred and recognised as
contract work in progress until the revenues and costs associated with the project are recognised.

(j) Cash and cash equivalents
Cash and cash equivalents comprises cash and demand deposits held with established financial institutions
and highly liquid investments, which are readily convertible into cash and have maturities of three months or
less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of
changes in value.

(k) Accounts receivable
Trade receivables are recognised initially at fair value and subsequently measured at amortised cost, less
 provision for doubtful debts.

Collectibility of trade receivables is reviewed on an ongoing basis. Debts which are known to be uncollectible
are written off. A provision for doubtful receivables is established when there is objective evidence that the
Company will not be able to collect all amounts due according to the original terms of receivables.

(l) Property, plant and equipment
Property, plant and equipment is stated at historical cost less depreciation. Historical cost includes
expenditure that is directly attributable to the acquisition of the items.

Subsequent costs are included in the asset’s carrying amount or recognised as a separate asset, as
appropriate, only when it is probable that future economic benefits associated with the item will flow to the
Company and the cost of the item can be measured reliably. All other repairs and maintenance are charged to
the income statement during the financial period in which they are incurred.

Depreciation is determined principally using the straight-line method to allocate their cost, net of their residual
values, over their estimated useful lives, as follows:

Scientific equipment 4 years
Computer equipment 2 years
Office furniture, fixtures & fittings 4 years
Leasehold Improvements Term of lease

(m) Intangible assets

Intellectual property
Acquired patents, trademarks and licences have finite useful lives and are carried at cost less accumulated
amortisation and impairment losses. Amortisation is calculated using the straight line method to allocate the
cost over the anticipated useful lives, which are aligned with the unexpired patent term or agreement over
trademarks and licences.

Acquired software
Acquired software licences are capitalised on the basis of the costs incurred to acquire and bring to use the
specific software. These costs are amortised over their estimated useful lives (two years).

(n) Employee benefits
Wages and salaries and annual leave
Liabilities for wages and salaries, bonuses and annual leave expected to be settled within 12 months of the
reporting date are recognised in accrued liabilities in respect of employees’ services up to the reporting date
and are measured at the amounts expected to be paid when the liabilities are settled. Liabilities for non-
accumulating sick leave are recognised when the leave is taken and measured at the rates paid or payable.

Share-based payments
Neuren operates an equity-settled share option plan and awards certain employees and consultants share
options, from time to time, on a discretionary basis. The fair value of the services received in exchange for the
grant of the options is recognised as an expense with a corresponding increase in other reserve equity over
the vesting period. The total amount to be expensed over the vesting period is determined by reference to the
fair value of the options at grant date. At each balance sheet date, the Company revises its estimates of the
number of options that are expected to vest and become exercisable. It recognises the impact of the revision
of original estimates, if any, in the income statement, and a corresponding adjustment to equity over the
remaining vesting period.
Notes to the Interim Financial Statements (Unaudited) for the six months ended 30 June 2007

The proceeds received net of any directly attributable transaction costs are credited to share capital when the options are exercised.

(o) Share issue costs
Costs associated with the issue of shares which are recognised in shareholders’ equity are treated as a reduction of the amount collected per share.

(p) Financial instruments
Financial instruments recognised in the balance sheet include cash and cash equivalents, accounts receivable and accounts payable. The Company believes that the amounts reported for financial instruments approximate fair value due to their short-term nature.

The Company does not utilise derivative financial instruments.

(q) Earnings per share
Basic and diluted earnings per share is calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of ordinary shares outstanding during the period.

3. Segment information
Neuren predominantly operates in one business segment, being the research and development of therapeutic products for the treatment of brain injury and other diseases, and from one geographical location, being New Zealand.

4. Expenses

<table>
<thead>
<tr>
<th>Company and Group</th>
<th>June 2007 NZ$’000</th>
<th>June 2006 NZ$’000</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Loss before income tax includes the following specific expenses:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scientific equipment</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>Computer equipment</td>
<td>13</td>
<td>11</td>
</tr>
<tr>
<td>Fixtures and fittings</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Leasehold improvements</td>
<td>16</td>
<td>2</td>
</tr>
<tr>
<td>Total depreciation</td>
<td>45</td>
<td>25</td>
</tr>
<tr>
<td>Amortisation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intellectual property</td>
<td>415</td>
<td>415</td>
</tr>
<tr>
<td>Software</td>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td>Total amortisation</td>
<td>424</td>
<td>416</td>
</tr>
<tr>
<td>Remuneration of auditors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Audit fees</td>
<td>13</td>
<td>16</td>
</tr>
<tr>
<td>Taxation advisory fees</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total remuneration of auditors</td>
<td>13</td>
<td>16</td>
</tr>
<tr>
<td>Employee benefits expense</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salaries and wages</td>
<td>1,231</td>
<td>1,106</td>
</tr>
<tr>
<td>Share option compensation</td>
<td>46</td>
<td>35</td>
</tr>
<tr>
<td>Total employee benefits expense</td>
<td>1,277</td>
<td>1,141</td>
</tr>
<tr>
<td>Directors’ fees</td>
<td>85</td>
<td>113</td>
</tr>
<tr>
<td>Lease expense</td>
<td>146</td>
<td>33</td>
</tr>
</tbody>
</table>
5. Income tax

<table>
<thead>
<tr>
<th>Company and Group</th>
<th>June 2007 NZ$’000</th>
<th>June 2006 NZ$’000</th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) Income tax expense</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current tax</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Deferred tax</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Income tax expense</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(b) Numerical reconciliation of income tax expense to prima facie tax payable (receivable)

<table>
<thead>
<tr>
<th></th>
<th>Loss before income tax</th>
<th>Tax at the New Zealand tax rate of 33%</th>
<th>Tax effect of amounts not deductible (taxable) in calculating taxable income:</th>
<th>Deferred tax assets not recognised</th>
<th>Income tax expense</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(8,228)</td>
<td>(2,715)</td>
<td>Share option compensation 82</td>
<td>2,578</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Other expenses not deductible for tax purposes 55</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-</td>
</tr>
</tbody>
</table>

6. Loss per share

Basic net deficit per share is based upon the weighted average number of outstanding ordinary shares. For the periods ended 30 June 2005 and 2006, the Company’s potentially dilutive ordinary share equivalents (being the options over ordinary shares set out in note 12) have an anti-dilutive effect on loss per share and, therefore, have not been included in determining the total weighted average number of ordinary shares outstanding for the purpose of calculating diluted net deficit per share.

<table>
<thead>
<tr>
<th>Company and Group</th>
<th>June 2007 NZ$’000</th>
<th>June 2006 NZ$’000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loss after income tax</td>
<td>(8,228)</td>
<td>(3,936)</td>
</tr>
<tr>
<td>Weighted average shares outstanding</td>
<td>131,108,285</td>
<td>98,109,589</td>
</tr>
<tr>
<td>Basic and diluted loss per share</td>
<td>($0.06)</td>
<td>($0.04)</td>
</tr>
</tbody>
</table>

7. Cash and cash equivalents

<table>
<thead>
<tr>
<th>Company and Group</th>
<th>June 2007 NZ$’000</th>
<th>Dec 2006 NZ$’000</th>
<th>June 2006 NZ$’000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash</td>
<td>74</td>
<td>357</td>
<td>179</td>
</tr>
<tr>
<td>Demand and short-term deposits</td>
<td>4,432</td>
<td>10,252</td>
<td>8,889</td>
</tr>
<tr>
<td></td>
<td>4,506</td>
<td>10,609</td>
<td>9,068</td>
</tr>
</tbody>
</table>

8. Trade and other receivables

<table>
<thead>
<tr>
<th>Company and Group</th>
<th>June 2007 NZ$’000</th>
<th>Dec 2006 NZ$’000</th>
<th>June 2006 NZ$’000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade receivables</td>
<td>44</td>
<td>421</td>
<td>420</td>
</tr>
<tr>
<td>Prepayments</td>
<td>61</td>
<td>106</td>
<td>256</td>
</tr>
<tr>
<td>Sundry receivables and accruals</td>
<td>244</td>
<td>467</td>
<td>386</td>
</tr>
<tr>
<td></td>
<td>349</td>
<td>994</td>
<td>1,062</td>
</tr>
</tbody>
</table>
9. Property, plant and equipment

<table>
<thead>
<tr>
<th>Company and Group</th>
<th>Scientific Equipment NZ$’000</th>
<th>Computer Equipment NZ$’000</th>
<th>Fixtures &amp; Fittings NZ$’000</th>
<th>Leasehold Improvements NZ$’000</th>
<th>Total NZ$’000</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>As at 1 January 2006</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>42</td>
<td>249</td>
<td>103</td>
<td>32</td>
<td>426</td>
</tr>
<tr>
<td>Accumulated depreciation</td>
<td>(3)</td>
<td>(236)</td>
<td>(89)</td>
<td>(20)</td>
<td>(348)</td>
</tr>
<tr>
<td>Net book value</td>
<td>39</td>
<td>13</td>
<td>14</td>
<td>12</td>
<td>78</td>
</tr>
<tr>
<td><strong>Movements in the period ended 30 June 2006</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opening net book value</td>
<td>39</td>
<td>13</td>
<td>14</td>
<td>12</td>
<td>78</td>
</tr>
<tr>
<td>Additions</td>
<td>-</td>
<td>15</td>
<td>3</td>
<td>-</td>
<td>18</td>
</tr>
<tr>
<td>Depreciation</td>
<td>(5)</td>
<td>(11)</td>
<td>(7)</td>
<td>(2)</td>
<td>(25)</td>
</tr>
<tr>
<td>Closing net book value</td>
<td>34</td>
<td>17</td>
<td>10</td>
<td>10</td>
<td>71</td>
</tr>
<tr>
<td><strong>As at 30 June 2006</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>42</td>
<td>264</td>
<td>106</td>
<td>32</td>
<td>444</td>
</tr>
<tr>
<td>Accumulated depreciation</td>
<td>(8)</td>
<td>(247)</td>
<td>(96)</td>
<td>(22)</td>
<td>(373)</td>
</tr>
<tr>
<td>Net book value</td>
<td>34</td>
<td>17</td>
<td>10</td>
<td>10</td>
<td>71</td>
</tr>
<tr>
<td><strong>Movements in the period ended 31 December 2006</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opening net book value</td>
<td>34</td>
<td>17</td>
<td>10</td>
<td>10</td>
<td>71</td>
</tr>
<tr>
<td>Additions</td>
<td>2</td>
<td>22</td>
<td>49</td>
<td>192</td>
<td>265</td>
</tr>
<tr>
<td>Depreciation</td>
<td>(6)</td>
<td>(4)</td>
<td>(5)</td>
<td>(7)</td>
<td>(22)</td>
</tr>
<tr>
<td>Assets written off</td>
<td>-</td>
<td>-</td>
<td>(2)</td>
<td>(9)</td>
<td>(11)</td>
</tr>
<tr>
<td>Closing net book value</td>
<td>30</td>
<td>35</td>
<td>52</td>
<td>186</td>
<td>303</td>
</tr>
<tr>
<td><strong>As at 31 December 2006</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>44</td>
<td>67</td>
<td>105</td>
<td>192</td>
<td>408</td>
</tr>
<tr>
<td>Accumulated depreciation</td>
<td>(14)</td>
<td>(32)</td>
<td>(53)</td>
<td>(8)</td>
<td>(105)</td>
</tr>
<tr>
<td>Net book value</td>
<td>30</td>
<td>35</td>
<td>52</td>
<td>186</td>
<td>303</td>
</tr>
<tr>
<td><strong>Movements in the period ended 30 June 2007</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opening net book value</td>
<td>30</td>
<td>35</td>
<td>52</td>
<td>186</td>
<td>303</td>
</tr>
<tr>
<td>Additions</td>
<td>44</td>
<td>10</td>
<td>2</td>
<td>4</td>
<td>60</td>
</tr>
<tr>
<td>Depreciation</td>
<td>(8)</td>
<td>(13)</td>
<td>(8)</td>
<td>(16)</td>
<td>(45)</td>
</tr>
<tr>
<td>Closing net book value</td>
<td>66</td>
<td>32</td>
<td>46</td>
<td>174</td>
<td>318</td>
</tr>
<tr>
<td><strong>As at 30 June 2007</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>88</td>
<td>77</td>
<td>107</td>
<td>196</td>
<td>468</td>
</tr>
<tr>
<td>Accumulated depreciation</td>
<td>(22)</td>
<td>(45)</td>
<td>(61)</td>
<td>(22)</td>
<td>(150)</td>
</tr>
<tr>
<td>Net book value</td>
<td>66</td>
<td>32</td>
<td>46</td>
<td>174</td>
<td>318</td>
</tr>
</tbody>
</table>

During the period ended 31 December 2006 the Company moved premises and at that time fully depreciated assets and leasehold improvements related to the previous tenancy were written off.
10. Intangible assets

<table>
<thead>
<tr>
<th></th>
<th>Acquired Patents NZ$’000</th>
<th>Purchased Software NZ$’000</th>
<th>Total NZ$’000</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>As at 1 January 2006</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>12,461</td>
<td>8</td>
<td>12,469</td>
</tr>
<tr>
<td>Accumulated amortisation</td>
<td>(1,660)</td>
<td>-</td>
<td>(1,860)</td>
</tr>
<tr>
<td>Net book value</td>
<td>10,801</td>
<td>8</td>
<td>10,809</td>
</tr>
<tr>
<td><strong>Movements in the period ended 30 June 2006</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opening net book value</td>
<td>10,801</td>
<td>8</td>
<td>10,809</td>
</tr>
<tr>
<td>Additions</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Amortisation</td>
<td>(415)</td>
<td>(1)</td>
<td>(416)</td>
</tr>
<tr>
<td>Closing net book value</td>
<td>10,386</td>
<td>7</td>
<td>10,393</td>
</tr>
<tr>
<td><strong>As at 30 June 2006</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>12,461</td>
<td>8</td>
<td>12,469</td>
</tr>
<tr>
<td>Accumulated amortisation</td>
<td>(2,075)</td>
<td>(1)</td>
<td>(2,076)</td>
</tr>
<tr>
<td>Net book value</td>
<td>10,386</td>
<td>7</td>
<td>10,393</td>
</tr>
<tr>
<td><strong>Movements in the period ended 31 December 2006</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opening net book value</td>
<td>10,386</td>
<td>7</td>
<td>10,393</td>
</tr>
<tr>
<td>Additions</td>
<td>-</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Amortisation</td>
<td>(416)</td>
<td>(3)</td>
<td>(419)</td>
</tr>
<tr>
<td>Closing net book value</td>
<td>9,970</td>
<td>16</td>
<td>9,986</td>
</tr>
<tr>
<td><strong>As at 31 December 2006</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>12,461</td>
<td>20</td>
<td>12,481</td>
</tr>
<tr>
<td>Accumulated amortisation</td>
<td>(2,491)</td>
<td>(4)</td>
<td>(2,495)</td>
</tr>
<tr>
<td>Net book value</td>
<td>9,970</td>
<td>16</td>
<td>9,986</td>
</tr>
<tr>
<td><strong>Movements in the period ended 30 June 2007</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opening net book value</td>
<td>9,970</td>
<td>16</td>
<td>9,986</td>
</tr>
<tr>
<td>Additions</td>
<td>-</td>
<td>17</td>
<td>17</td>
</tr>
<tr>
<td>Amortisation</td>
<td>(415)</td>
<td>(9)</td>
<td>(424)</td>
</tr>
<tr>
<td>Closing net book value</td>
<td>9,555</td>
<td>24</td>
<td>9,579</td>
</tr>
<tr>
<td><strong>As at 30 June 2007</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>12,461</td>
<td>37</td>
<td>12,498</td>
</tr>
<tr>
<td>Accumulated amortisation</td>
<td>(2,906)</td>
<td>(13)</td>
<td>(2,919)</td>
</tr>
<tr>
<td>Net book value</td>
<td>9,555</td>
<td>24</td>
<td>9,579</td>
</tr>
</tbody>
</table>

11. Trade and other payables

<table>
<thead>
<tr>
<th>Company and Group</th>
<th>June 2007 NZ$’000</th>
<th>Dec 2006 NZ$’000</th>
<th>June 2006 NZ$’000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade payables</td>
<td>3,662</td>
<td>2,454</td>
<td>1,993</td>
</tr>
<tr>
<td>Accruals</td>
<td>262</td>
<td>204</td>
<td>218</td>
</tr>
<tr>
<td>Employee benefits</td>
<td>291</td>
<td>467</td>
<td>372</td>
</tr>
<tr>
<td>Payment on account</td>
<td>323</td>
<td>573</td>
<td>632</td>
</tr>
<tr>
<td></td>
<td>4,538</td>
<td>3,698</td>
<td>3,215</td>
</tr>
</tbody>
</table>
Notes to the Interim Financial Statements (Unaudited)
for the six months ended 30 June 2007

12. Share capital

(a) Ordinary Shares
The ordinary shares have no par value and all ordinary shares are fully paid-up and rank equally as to dividends and liquidation, with one vote attached to each fully paid ordinary share.

(b) Share Options
On 19 May 2005 the Company granted 3,000,000 options (“May 2005 Options”) for future consulting services related to capital raising and financing activities. The options were exercisable into ordinary shares on a one-for-one basis with an exercise price of A$0.50 per share. The options expired on 31 May 2007.

Oceania & Eastern Biotech Limited is an investment company associated with interests of Dr Robin Congreve and holds 1,528,892 options (the “O&E Options”). The O&E Options’ exercise price is a fixed sum of NZ$600,000, exercisable into 1,528,892 ordinary shares (equivalent to NZ$0.392 per share). The options may be exercised at any time up to and including 31 March 2009.

Auckland UniServices Limited (“UniServices”) is the commercial research and knowledge transfer company for the University of Auckland and holds 1,872,892 options (“UniServices Options”). The UniServices Options’ exercise price is a fixed sum of NZ$735,000, exercisable into 1,872,892 ordinary shares (equivalent to NZ$0.392 per share). The UniServices Options may be exercised at any time up to the earlier of two years following the termination of the Research Deed (or any further such deed entered into between the Company and UniServices Limited) and 31 March 2009.

The above options were otherwise issued on terms and conditions not materially different to those of the Share Option Plan described below.

The Company has established a Share Option Plan to assist in the retention and motivation of senior employees of, and certain consultants to, the Company (“Participants”). Under the Share Option Plan, options may be offered to Participants by the Remuneration and Audit Committee. The maximum number of options to be issued and outstanding under the Share Option Plan was amended by shareholders in 2005 to 15% of the issued ordinary shares of the Company at any time. No payment is required for the grant of options under the Share Option Plan. Each option is an option to subscribe in cash for one ordinary share, but does not carry any right to vote. Upon the exercise of an option by a Participant, each ordinary share issued will rank equally with other ordinary shares of the Company. Options granted under the Share Option Plan generally vest over three years service by the Participant and lapse five years after grant date.

Movements in the number of share options are as follows:

<table>
<thead>
<tr>
<th></th>
<th>Options</th>
<th>Weighted Average Exercise Price (NZ$)</th>
<th>Exercisable</th>
<th>Weighted Average Exercise Price (NZ$)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Outstanding at 1 January 2006</strong></td>
<td>21,257,627</td>
<td>$0.412</td>
<td>20,192,065</td>
<td>$0.413</td>
</tr>
<tr>
<td>Granted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Expired/forfeited/exercised</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Outstanding at 30 June 2006</strong></td>
<td>21,257,627</td>
<td>$0.412</td>
<td>20,358,733</td>
<td>$0.425</td>
</tr>
<tr>
<td>Granted</td>
<td>600,000</td>
<td>$0.472</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Expired/forfeited/exercised</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Outstanding at 31 December 2006</strong></td>
<td>21,857,627</td>
<td>$0.417</td>
<td>20,924,295</td>
<td>$0.415</td>
</tr>
<tr>
<td>Granted</td>
<td>1,800,000</td>
<td>$0.670</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Exercised</td>
<td>(20,000)</td>
<td>$0.392</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Expired/forfeited</td>
<td>(3,000,000)</td>
<td>$0.555</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Outstanding at 30 June 2007</strong></td>
<td>20,637,627</td>
<td>$0.419</td>
<td>19,890,961</td>
<td>$0.416</td>
</tr>
</tbody>
</table>
Notes to the Interim Financial Statements (Unaudited)
for the six months ended 30 June 2007

The weighted average remaining contractual life of outstanding share options is as follows:

<table>
<thead>
<tr>
<th>Exercise price range</th>
<th>June 2007</th>
<th>Dec 2006</th>
<th>June 2006</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Options</td>
<td>Weighted Average Remaining Contract Life (years)</td>
<td>Options</td>
</tr>
<tr>
<td>NZ$0.392 – NZ$0.472</td>
<td>18,837,627</td>
<td>1.9</td>
<td>18,857,627</td>
</tr>
<tr>
<td>A$0.50</td>
<td>-</td>
<td>-</td>
<td>3,000,000</td>
</tr>
<tr>
<td>A$0.60</td>
<td>1,800,000</td>
<td>1.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>20,637,627</td>
<td>1.8</td>
<td>21,857,627</td>
</tr>
</tbody>
</table>

The weighted average assessed fair value of options granted during the period determined using the Black-Scholes valuation model was NZ$0.11 per option (Dec 2006: NZ$0.22). The significant weighted average inputs into the model were a grant date share price of NZ$0.570 (Dec 2006: NZ$0.472), volatility of 66% (Dec 2006: 65%), dividend yield of 0% (Dec 2006: 0%), an expected option life of 1.9 years (Dec 2006: 3.0 years), and an annual risk-free interest rate of 5.95% (Dec 2006: 5.95%). The expected price volatility was derived by analysing the historic volatility of the Company’s shares since listing on the ASX.

13. Deferred tax

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NZ$'000</td>
<td>NZ$'000</td>
<td>NZ$'000</td>
</tr>
<tr>
<td>Deferred tax asset (liability)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amounts recognised in profit or loss</td>
<td>106</td>
<td>106</td>
<td>80</td>
</tr>
<tr>
<td>Provisions and accruals</td>
<td>16</td>
<td>12</td>
<td>24</td>
</tr>
<tr>
<td>Property, plant and equipment</td>
<td>353</td>
<td>376</td>
<td>218</td>
</tr>
<tr>
<td>Intangible assets</td>
<td>9,180</td>
<td>6,583</td>
<td>4,404</td>
</tr>
<tr>
<td>Tax losses</td>
<td>9,655</td>
<td>7,077</td>
<td>4,726</td>
</tr>
<tr>
<td>Unrecognised deferred tax assets</td>
<td>(9,655)</td>
<td>(7,077)</td>
<td>(4,726)</td>
</tr>
<tr>
<td>Deferred tax asset (liability)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Movements</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deferred tax asset (liability) at the beginning of the period</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Credited (charged) to the income statement (note 5)</td>
<td>2,578</td>
<td>3,605</td>
<td>1,254</td>
</tr>
<tr>
<td>Change in unrecognised deferred tax assets (note 5)</td>
<td>(2,578)</td>
<td>(3,605)</td>
<td>(1,254)</td>
</tr>
<tr>
<td>Deferred tax asset (liability) at the end of the period</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

14. Group financial statements and investments in subsidiaries

Neuren Pharmaceuticals Limited has the following subsidiaries:

<table>
<thead>
<tr>
<th>Name of entity</th>
<th>Date of incorporation</th>
<th>Principal activities</th>
<th>Interest held</th>
<th>Domicile</th>
</tr>
</thead>
<tbody>
<tr>
<td>AgVentures Limited</td>
<td>7 October 2003</td>
<td>Dormant</td>
<td>100%</td>
<td>New Zealand</td>
</tr>
<tr>
<td>NeuroendocrinZ Limited</td>
<td>10 July 2002</td>
<td>Dormant</td>
<td>100%</td>
<td>New Zealand</td>
</tr>
<tr>
<td>Neuren Pharmaceuticals Inc.</td>
<td>20 August 2002</td>
<td>US Based Office</td>
<td>100%</td>
<td>USA</td>
</tr>
<tr>
<td>Neuren Pharmaceuticals (Australia) Pty Ltd</td>
<td>9 November 2006</td>
<td>Dormant</td>
<td>100%</td>
<td>Australia</td>
</tr>
</tbody>
</table>

All subsidiaries have a balance date of 31 December. The subsidiaries have had no material impact on the financial performance or position of the Company or Group to 30 June 2007.
Notes to the Interim Financial Statements (Unaudited)
for the six months ended 30 June 2007

15. Commitments and contingencies

(a) Operating leases
The following aggregate future non-cancellable minimum lease payments for premises have been committed to by the Company, but not recognised in the financial statements. The premises commitment is for a six year lease, with two three year rights of renewal and three yearly rental reviews.

<table>
<thead>
<tr>
<th>Company and Group</th>
<th>Jun 2007 NZ$’000</th>
<th>Dec 2006 NZ$’000</th>
<th>Jun 2006 NZ$’000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not later than one year</td>
<td>237</td>
<td>237</td>
<td>346</td>
</tr>
<tr>
<td>Later than one year and not later than five years</td>
<td>948</td>
<td>948</td>
<td>1,156</td>
</tr>
<tr>
<td>Later than five years</td>
<td>99</td>
<td>217</td>
<td>336</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>1,284</strong></td>
<td><strong>1,402</strong></td>
<td><strong>1,838</strong></td>
</tr>
</tbody>
</table>

(b) Legal claims
The Company has not entered into any collaborative arrangements and has no other significant legal contingencies as at 30 June 2007 (December and June 2006: nil).

(c) Capital commitments
The Company is not committed to the purchase of any property, plant or equipment as at 30 June 2007 (December and June 2006: nil).

16. Related party transactions

(a) Key management and personnel compensation
The key management personnel include the directors of the Company and the direct reports to the Managing Director (CEO). Compensation was as follows:

<table>
<thead>
<tr>
<th>Company and Group</th>
<th>June 2007 NZ$’000</th>
<th>June 2006 NZ$’000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short-term benefits</td>
<td>1,013</td>
<td>860</td>
</tr>
<tr>
<td>Share-based payments</td>
<td>46</td>
<td>35</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>1,059</strong></td>
<td><strong>895</strong></td>
</tr>
</tbody>
</table>

(b) Subsidiaries
Interests in subsidiaries are set out in note 14.

17. Events after balance date
On 31 July 2007 the Company entered into a binding term sheet to acquire 100% of Hamilton Pharmaceuticals Inc. in exchange for US$4.4 million in Neuren ordinary shares at the average closing price for the preceding five trading days, which was A$0.354 (the Purchase Share Price).

Hamilton is a privately-held biopharmaceutical company based in the U.S., whose principal asset is Motiva™, or nefracetam, a novel cyclic GABA derivative that Neuren intends to conduct a Phase 2 clinical trial for in post-stroke depression. Motiva™ has previously demonstrated safety and efficacy in clinical trials through to Phase 2b. The ongoing operating costs for Hamilton are negligible, and the Company does not intend to retain any of Hamilton’s personnel.

As a result of the acquisition, the investors in Hamilton, Vivo Ventures, LLC and associates, Index Ventures, and CNF Investments, LLC, will become shareholders in Neuren. Upon closing, two of these investors, Vivo and CNF, will invest US$3 million in a convertible note issued by the Company which will convert into securities of the Company on the date of, and on the same terms of issue as, the next capital raising in which Neuren has received subscriptions for, and issued, new securities in Neuren for an aggregate of at least US$5 million.

In addition, Neuren will be obligated to make the following payments to Hamilton’s shareholders that are contingent upon the Company’s ability to achieve certain development milestones for Motiva™:

- US$0.5 million in warrants to purchase our ordinary shares at the Purchase Share Price upon successful completion of a Phase 2 trial with results adequate to support initiation of a Phase 3 study;
- US$0.5 million in warrants to purchase our ordinary shares at the Purchase Share Price upon initiation of a pivotal Phase 3 trial;
Motiva™ is also subject to future milestone payments and royalties to Daiichi Pharmaceutical Co., Ltd., now Daiichi Sankyo Co., Ltd., pursuant to an existing license agreement between Daiichi and Hamilton.

The acquisition is conditional on the approval of Neuren’s shareholders at a meeting scheduled for September 2007, and accordingly acquisition values have yet to be determined. If approved, the acquisition will result in the issue of approximately 14,635,000 ordinary shares to acquire Hamilton, and the Company will receive US$3 million in cash for the issue of the convertible notes noted above.

There are no other events subsequent to 30 June 2007 to report for the Company or its subsidiaries as at 29 August 2007.

18. Financial Instruments

The Company and its subsidiaries are subject to a number of financial risks which arise as a result of its activities.

Currency Risk
During the normal course of business the Company and its subsidiaries enter into contracts with overseas customers or consultants that are denominated in foreign currency. As a result of these transactions there is exposure to fluctuations in foreign exchange rates.

At 30 June 2007 the unrecognised notional or principal contract amount of foreign exchange instruments outstanding was $nil (31 December and 30 June 2006: $nil).

Interest Rate Risk
The following disclosures identify the periods in which interest rates are subject to review on interest bearing financial assets. Interest on short-term deposits is at variable rates which are frequently reviewed.

The effective interest rates on short term deposits at 30 June 2007 were New Zealand dollar denominated deposits of NZ$303,000 at 8.0%, Australian dollar denominated deposits of A$1,678,000 at 6.1%, British pound denominated deposits of £276,000 at 5.4%, and US dollar denominated deposits of US$1,225,000 at 5.1%. (31 December 2006: NZ$369,000 at 7.3%, A$6,314,000 at 6.0%, £176,000 at 4.8%, and US$1,699,000 at 5.2%; 30 June 2006: NZ$1,454,000 at 7.3%, A$2,670,000 at 5.6%, £275,000 at 4.4%, and US$2,026,000 at 5.1%).

Trade receivables and payables are not interest rate sensitive.

Credit Risk
The Company and its subsidiaries incur credit risk from transactions with trade receivables and financial institutions in the normal course of its business.

The Company and its subsidiaries do not require any collateral or security to support transactions with financial institutions. The counterparties used for banking and finance activities are financial institutions with high credit ratings.

Fair Values
Cash at bank, receivables, and accounts payable have a fair value equivalent to the carrying value in the financial statements.